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ABSTRACT AND KEY WORDS 
 
Background: Hypotension is the most common complication during 
spinal anesthesia. This study aimed to investigate the effects of 
dopamine on the intraoperative hemodynamics in patients undergoing 
surgeries under spinal anesthesia.  
 
Material/Methods: This is a randomised control study included 120  
patients undergoing elective surgeries under spinal anesthesia. 
Patients were randomly assigned into 4 groups (n=30 per 
group):Group A, GroupB, Group C and Group D to receive 
intravenous dopamine infusion @ 0, 3, 5, and 7 mcg/kg/minute 
respectively . Pulse rate, blood pressure,mean arterial pressure, ECG, 
SpO2  were recorded at varying intervals[T1(1st minute),T2(2nd 
minute),T3,T4,T5]then every 5 minutes upto 30 minutes, then every 
10 minutes till the end of the surgery. Urine output was measured 
every 60 minutes. 
 
Results:When systolic blood pressure was compared between group 
A and the other 3 groups,there was significant statistical difference 
between group A and C, A and D,from T2 to T90 minutes, and mean 
arterial pressure of the three groups B,C and D,compared with control 
group A,there was statistically significant difference seen between the 
groups A and C(T2-T100),A and D(T3,T10-T40).Diastolic blood 
pressure of the control group was compared with the other three 
groups B,C and D,there was no significant difference statistically.The 
heart rate of group A is compared with other three groups there was 
no consistent statistical difference till T30 in group A Vs C, A Vs 
D,but after T30 minutes there was significant fall in the heart rate in 
group A when compared to other 3 groups.There was a significant 
difference in urine output noted between the control group A and 
groups which received dopamine infusion.The average volume of 
urine in control group is 73.9 ml at the end of 60 minutes,but it was 
around 10 times more in group B , C and D. 
 
Conclusions: Continuous intravenous infusion of 5µg/kg/min 
dopamine is safe and effective in maintaining hemodynamic stability 
in patients undergoing surgeries under spinal anaesthesia. 
 
Keywords: Anesthesia,spinal,Hemodynamics,dopamine 
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INTRODUCTION 
 
Spinal anaesthesia is one of the most popular and widely used 
anaesthetic procedures. It is a simple, cost effective and efficient 
technique that provides complete sensory and motor block, as well as 
postoperative analgaesia with a high success rate. Several advantages 
of spinal anaesthesia include a decreased incidence of deep vein 
thrombosis, reduced intraoperative blood loss, as well as the 
prevention of pulmonary aspiration in case of emergency, especially in 
patients with potential airway problems and known respiratory 
diseases.  
Although sub arachnoid block provide excellent anaesthesia for 
many surgeries, it is frequently accompanied by hypotension. This is 
largely due to the result of sympathetic nerve blockade. Excessive 
hypotension may potentially produce myocardial ,cerebral and renal 
ischaemia. 
Methods to prevent and treat this hypotension has been the 
subject of much investigation and controversy. One of the mainstays 
of management is the use of vasopressor agents and those currently 
available are not perfect.  
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In this study, the role of dopamine as a vasopressor in spinal 
hypotension is being studied. Ephedrine was the first agent used for 
this purpose and it has withstood the test of time,it is the agent against 
which all others are compared. It remains the first-line agent in spinal 
anaesthesia induced hypotension, but it cannot be relied upon to be 
100% successful and other agents must be considered when it is 
inadequate.  
Hence in this study the effects of various doses of dopamine 
continuous intravenous infusion on the intraoperative hemodynamics 
in patients undergoing elective surgeries under spinal anaesthesia was 
studied to decide about the appropriate dose of dopamine needed to 
prevent hypotension in patients undergoing surgeries under spinal 
anaesthesia. 
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Physiology of spinal anaesthesia 
  
  It is important to understand the alterations in physiology produced 
by sub-arachnoid blockade in order to make rational choices in 
managing the resulting hypotension. Spinal block results in a number 
of changes in the cardiovascular system which may all contribute to 
the associated hypotension.Essentially, all of the cardiovascular 
effects of spinal anaesthesia are mediated by blockade of the 
preganglionic sympathetic neurones produced when local anaesthetic 
is injected into the subarachnoid space. 
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1) Reduction in vasomotor tone  
   This results in arterial and arteriolar vasodilatation, as a direct 
result of the sympathetic neurone blockade, producing hypotension1. 
Compensatory vasoconstriction may occur in the upper part of the 
body above the block, as a result of baroreceptor activity2. 
Consequently, those areas with intact sympathetic innervation may be 
shown to be vasoconstricted as demonstrated by a decrease in skin 
temperature ,and a decrease in forearm blood flow. As the upper arm 
blood flow is less than 5% of the cardiac output, the ability to 
compensate for vasodilatation in the lower body is limited3.  
a)Arterial Circulation (Afterload) 
      Afterload is the measure of resistance against which the left 
ventricle must eject blood. It may be measured as the stress (or tension) 
that is developed in the ventricular wall during systole. Neuraxial 
anesthesia decreases afterload by producing arterial vasodilation.This 
vasodilatation, however, is not equivalent in all vascular beds. For 
instance, muscle and skin blood flow may be decreased by 
sympathectomy, whereas the total blood flow to the same extremity 
may be more than quadrupled4,5. 
 Additionally, the extent to which afterload is decreased by 
sympathetic denervation varies considerably from one patient to 
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another. Therefore, patients with equivalent sympathetic denervation 
do not necessarily demonstrate equal changes in afterload. Young and 
robust patients are able to maintain peripheral resistance better than 
elderly or cachectic patients. The extent to which vascular tone is 
maintained in various organs is also variable. It is retained most 
effectively in renal and splanchnic vasculature, less so in skeletal 
muscle, and least effectively in skin vessels. 
When arterial vasodilation results from sympathetic denervation, a 
simultaneous, compensatory reflex vasoconstriction occurs in areas of 
the body in which the sympathetic nervous system is intact, usually in 
areas cephalad to the site of spinal anesthetic block. The effectiveness 
of this reflex vasoconstriction in maintaining normotension is a 
function of the extent of the sympathetic block. If, for instance, 
sympathetic denervation reaches the fourth thoracic dermatome (T4) 
or higher, the intact upper limb vasculature may contribute only 5% of 
the total cardiac output (CO). Even maximal vasoconstriction will be 
insufficient to compensate for the profound arterial vasodilation in the 
rest of the body. Reflex cerebral vasoconstriction does not occur, 
because of the intrinsic cerebral autoregulatory mechanisms. 
 
 
  
6 
 
b)Venous Circulation (Preload) 
Preload is a measure of the volume of venous blood returned to the 
right ventricle from the periphery. Sympathetic denervation associated 
with central neuraxial block dilates not only the arterial and 
postarteriolar circulation (afterload), but also the venous circulation. 
Neural innervation of the venous circulation is similar to that of the 
arterial circulation, and areas of vasodilation will be equivalent. 
However, the degree of vasodilation in the arterial and venous sides of 
the circulation is markedly different. Because the arterial walls contain 
more smooth muscle fibers and supporting structures (media) than 
their venous counterparts, sympathetic denervation results in less 
vasodilation in afterload vessels, because they maintain their own 
intrinsic vascular tone. In contrast, the preload (venous) vasculature 
undergoes maximal dilatation, and venous capacitance increases 
maximally. This change results in the rapid pooling of an abnormally 
large volume of blood in the periphery and a marked decrease in the 
blood volume returning to the right ventricle, resulting in a significant 
decrease in CO and a decrease in BP. 
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2) Loss of cardio accelerator nerve function 
Blockade above the T5 level results in the removal of the 
chronotropic and inotropic influence of the sympathetic nervous 
system.Peripheral venodilation also diminishes venous return, which 
contributes to the bradycardia. Cardiac output, and hence blood 
pressure, may therefore fall6,7. 
  
i)Heart Rate 
Slowing of the HR is characteristically associated with neuraxial 
anesthesia, and the extent of bradycardia correlates well with the 
extent of sympathetic denervation. However, the relation between 
denervation and the degree of bradycardia may be modified by a 
number of other factors including age, coadministration of intravenous 
drugs, and the position of the patient on the operating room table. 
Importantly, bradycardia during high (thoracic) levels of spinal 
anesthesia is due to two main factors:  
(i) denervation of preganglionic cardiac accelerator fibers (T1-T4)  
(ii) diminished venous return to the right ventricle because of 
decreases in preload.  
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In extreme cases, the rapid decrease in venous return to the right 
ventricle (due to massive hemorrhage or assumption of head-up 
positioning during spinal anesthetic-induced near-total 
sympathectomy) may result in activation of mechanoreceptors and 
chemoreceptors in the ventricle. This activation results in severe 
bradycardia or asystole due to further increases in parasympathetic 
activity and inhibition of sympathetic activity (Bezold-Jarisch reflex 
induced asystole). 
ii)Cardiac Output 
Reduced Cardiac Output following spinal anesthesia is one of the 
most consistent findings reported in the literature and is the sine qua 
non of neuraxial anesthesia. The extent of Cardiac Output decrease 
also is a function of the degree of sympathetic denervation. Because 
one of the many determinants of Cardiac Output is the amount of 
blood in the ventricle (preload), and preload is exquisitely sensitive to 
the effects of gravity, marked changes in Cardiac Output may be 
induced by patient positioning. Placing patients undergoing neuraxial 
anesthesia in the horizontal position while elevating the legs will 
facilitate venous return to the heart and tends to maintain Cardiac 
Output and BP. Conversely, assumption of an even slight head-up 
position during neuraxial anesthesia with high levels of sympathetic 
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denervation (in the misguided attempt to prevent further extension of 
the spinal block) may have catastrophic consequences such as 
profound bradycardia, cerebral hypoperfusion, and cardiac 
arrest.Reports of severe complications related to improper positioning 
of patients (i.e., head-up) during high levels of spinal anesthesia have 
spanned the last six decades8,9. 
iii)Myocardial Work10 
Because high levels of sympathetic denervation are associated 
with decreased afterload (and preload), the amount of work performed 
by the heart er unit time is decreased. Eckenhoff demonstrated in dogs 
with a spinal-induced total sympathectomy, a 66% decrease in left 
ventricular work.The significant decrease in myocardial work is due 
primarily to three factors:  
(i) decrease in heart rate 
(ii) decrease in arterial/total peripheral resistance (afterload) 
(iii) decrease in stroke volume of the left ventricle secondary to the 
decreased preload. 
iv)Myocardial Irritability11 
It would seem unlikely that myocardial irritability should be 
increased during high levels of sympathetic denervation produced by 
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neuraxial anesthesia. Indeed, the development of tachyarrhythmia has 
not been reported. There are, however, reports of sinus bradycardia 
and even asystole in patients with sick sinus syndrome undergoing 
spinal anesthesia. 
v)Coronary Perfusion12,13,14 
Perfusion is determined by the difference between the driving 
force (mean aortic pressure) and the coronary vascular resistance. The 
sympathectomy-induced decrease in mean aortic pressure does not 
have a deleterious effect on coronary perfusion because of coronary 
circulation autoregulation. The decrease in coronary perfusion 
pressure is compensated by several factors:  
(i) decreased ventricular intramural pressure during diastole, when 
coronary perfusion takes place;  
(ii) decreased rate of contraction of the ventricle, which decreases 
myocardial oxygen demand;  
 (iii) coronary autoregulation.  
 Hackel et al reported that in patients with high spinal 
anesthetic-sympathetic denervation, the mean arterial pressure 
decrease (48%) was compensated by a relatively larger decrease in 
myocardial work and oxygen utilization (53%). 
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Neuraxial anesthesia also induces favorable changes in the 
distribution of coronary blood flow. Following myocardial infarction, 
sympathetic blockade associated with high thoracic epidural 
anesthesia increases subendocardial perfusion more than epicardial 
flow by decreasing left ventricular end-diastolic pressure and left 
ventricular wall tension.Similar beneficial effects of thoracic epidural 
anesthesia were reported in patients with unstable angina pectoris. 
 
3)Systemic uptake of local anaesthetic  
   Equal doses of local anaesthetic administered into the 
subarachnoid and epidural spaces produce similar plasma 
concentrations of drug (75 mg lidocaine produce a plasma 
concentration of 0.32 + 0.07 mg/ ml after subarachnoid injection 
versus 0.41 + 0.07 mg/ml after epi- dural injection), but the absorption 
is more rapid from the epidural space, presumably because of its 
greater vascularity. The much smaller doses of local anaesthetic used 
for a spinal block can be expected to have little systemic effect, but the 
absorption of large doses from the epidural space may be 
considerable. Local anaesthetics used intravenously for control of 
cardiac arrhythmias are known to cause myocardial depression and it 
has been shown that epidural administration of such drugs will also 
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produce plasma concentrations great enough for systemic effects to be 
produced (blood lidocaine concentrations have been measured at 
between 3 and 7 mg/ml. It has been shown that lumbar epidural 
anaesthesia (without blocking the cardio accelerator fibres) can reduce 
cardiac output and arterial blood pressure15,16,17,18.  
 
4)other factors  
   Neuraxial anesthesia-induced hypotension usually develops in the 
first 15 to 20 minutes. Many factors influence the time course of 
hypotension, including: 
 Speed of injection 
 Total dose and/or volume and concentration of local anesthetic 
 Intravascular volume status 
 Patient positioning  
 Patient comorbidities (hypertension, diabetes and autonomic 
dysfunction, chronic diuretic or beta-blockade therapy, etc.) 
Severe hypotension from spinal anesthesia may be predicted reliably 
by analyzing HR variability, which is an indirect measure of 
autonomic control. 
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      If spinal anaesthesia is performed in a standardised manner on 
a large series of patients, keeping the height of block and position of 
the patient constant in all cases, some patients will show very little 
alteration in blood pressure while others will show pronounced 
hypotension. There may be many reasons for this variabilty in 
response, such as pregnancy,old age, pre-existing hypertension or 
cardiovascular disease, and hypovolaemia.  
 
  Patients with pre-existing hypertension undergoing spinal 
anaesthesia show a much greater decrease in blood pressure and 
peripheral vascular resistance than normotensive patients with 
equivalent levels of anaesthesia. Age is a major factor in determining 
the haemodynamic response to spinal anaesthesia, the degree of 
hypotension increasing with increasing age.The effect of co-existing 
medical disease on hypotension induced by spinal anaesthesia can also 
be shown to be of importance. Patients in ASA class III may produce a 
more pronounced hypotensive response than patients in ASA classes I 
or II. Spinal anaesthesia in the presence of hypovolaemia may be 
associated with severe hypotension and cardiovascular depression, and 
should be avoided in this situation whenever possible19,20. 
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MANAGEMENT OF HYPOTENSION IN SPINAL 
ANAESTHESIA 
    
  Hypotension could be a major problem with spinal anaesthesia. The 
management of this problem therefore became important in order that 
the quality of anaesthesia produced by these blocks could be matched 
by safety. 
   Methods developed for the management of the hypotension fall 
into four categories:  
       i Volume expansion 
       ii Physical methods to increase in venous return. 
       iii Prevention or treatment of associated bradycardia  
       iv Vasoconstriction 
 These techniques have been used separately and in combination with 
varying degrees of success, and the optimal form of management 
remains the subject of much discussion. 
(i) Volume expansion  
      It is common practice to infuse large volumes (10-20 ml. kg ) 
of electrolyte crystalloid solution (e.g., saline 0.9%) rapidly to help 
prevent or to treat hypotension induced by a spinal block21. This will 
increase venous return and therefore cardiac output22,23.Haemodilution 
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also Occurs, which will improve peripheral circulation, but this may 
be at the expense of oxygen delivery24. The use of excessive volumes 
of crystalloid may therefore do more harm than good. Crystalloid 
preloading may also be relatively ineffectual in preventing 
hypotension25.  
 Although preloading reduced the incidence of 
hypotension, there was still a considerable proportion of the patients 
who became hypotensive and the clinical relevance of the reduction in 
the incidence of hypotension is questionable. A further problem is the 
increased need for catheterisation as a result of developing urinary 
retention as a combined effect of the spinal block itself and the fluid 
load given. Large fluid loads may be poorly tolerated by patients with 
limited myocardial reserve or with a relatively fixed cardiac output 
because of valvular heart disease. Some of these problems may be 
lessened by the use of smaller volumes of colloid solutions, but again 
this approach may not be completely successful, and colloid solutions 
have been known to produce anaphylactoid reactions in a small 
number of patients26. 
 It is therefore clear that intravenous fluids do not provide 
a complete solution to this problem. 
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(ii) Physical methods to increase venous return  
 Venous return can be augmented by elevating the 
patient's legs (providing the femoral veins remain unobstructed) or by 
the use of a head-down tilt. These manoeuvres alone may be sufficient 
to restore blood pressure to an acceptable level. However, this is not 
always the case and other methods must then be used. The head-down 
position may also be regarded as undesirable when hyperbaric local 
anaesthetic solutions are used because of concern over cephalad 
spread of the block27,28.  
 
(iii) Prevention or treatment of associated bradycardia  
 Spinal blockade affecting the upper thoracic spinal cord 
segments (T1-T4) produces bradycardia by blocking the 
cardioaccelerator nerve fibres, allowing vagal tone to dominate.As 
heart rate is one of the determinants of cardiac output and hence blood 
pressure, drugs with vagolytic actions (e.g., atropine) can be used to 
elevate heart rate and hence blood pressure. However, the response is 
erratic and the disadvantages may outweigh the benefits. In particular, 
the production of a tachycardia is undesirable in patients dependent on 
heart filling and coronary perfusion during diastole29.  
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(iv) vasoconstriction 
 Vasopressors are the mainstay in the management of 
spinal anaesthesia induced hypotension.Understanding the 
pathophysiology of sympathectomy-induced hypotension is extremely 
important in the selection of vasopressors for treatment. Cardiac 
output may be increased by increasing heart rate, increasing stroke 
volume, or both. Atropine may increase cardiac output through its 
chronotropic effects on heart rate. However, it is rarely effective by 
itself during sympathectomy-induced bradycardia and hypotension 
because of its lack of vasoconstrictive properties. In such instances, 
drugs that provide both chronotropic and venoconstrictive effects are 
preferred. 
Because severe hypotension and associated bradycardia in high 
sympathetic denervation result from the marked increase in venous 
capacitance, vasoactive substances should increase preload 
preferentially.  
A vasoconstrictor that predominantly increases afterload (on a 
background of low preload) may increase peripheral BP toward 
normal, but will further decrease perfusion pressure to the core organs 
because of arterial vasoconstriction. Mixed adrenergic agonists (such 
as ephedrine,dopamine) correct hypotension more effectively than 
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either pure alpha-adrenergic (phenylephrine) or beta-adrenergic 
(isoproterenol) agonists. Ephedrine provides both venoconstriction 
and chronotropy, thereby reversing the effects of denervation of the 
T1-4 cardio-accelerator fibers. On the other hand, an agent such as 
phenylephrine may increase afterload by increasing arterial 
vasoconstriction and further induce reflex bradycardia. Of the 
currently available sympathomimetic amines, norephinephrine has the 
most venoconstrictive properties, followed by metaraminol, ephedrine, 
mephentermine, and phenylephrine. 
History of the use of vasopressor agents: 
    Ephedrine was the first agent to be used successfully to treat 
hypotension induced by spinal anaesthesia, in 1927. Later research 
examined the effects of other drugs, including paredrine, methedrine, 
pitressinephedrine combination,  and later methoxamine, 
phenylephrine,  metaraminol, mephentermine,  dopamine  and 
dobutamine.   
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Dopamine30: 
 Dopamine is an endogenous catecholamine that is the 
immediate precursor of norepinephrine. Dopamine regulates cardiac, 
vascular, and endocrine function and is an important neurotransmitter 
in the central and peripheral nervous systems.  
 The pharmacology of dopamine is complex as this 
catecholamine differentially stimulates a variety of dopaminergic as 
well as adrenergic receptors. It is a relatively nonspecific agonist at 
both dopamine1 (D1) and dopamine2 (D2) receptors and the α- and 
β-adrenergic receptors. D1 receptors are located postsynaptically.  
 
Mechanism of action 
When activated D1 receptors elicit vasodilation in renal, 
mesenteric, coronary, and cerebral vascular beds and inhibition of 
sodium–potassium adenosine triphosphatase .Activation of these 
receptors is mediated by adenylate cyclase stimulation. D2 receptors 
are principally presynaptic and inhibit adenylate cyclase activity and 
release of norepinephrine in autonomic nervous system ganglia and 
adrenergic nerves (in renal and mesenteric vessels) leading to 
vasodilation. D2 receptors are also present in the pituitary gland, 
emetic center of the medulla, and kidney. Nausea and vomiting 
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produced by dopamine probably reflect stimulation of D2 receptors. 
Dopamine receptors may also be associated with the neural 
mechanism for “reward” that is associated with cocaine and alcohol 
dependence. 
Pharmacokinetics 
Traditionally, the pharmacokinetics of dopamine has been 
attributed to dose-dependent effects on varying receptors.At low 
intravenous (IV) infusion rates (0.5 to 3 µg/kg/minute), dopamine 
primarily stimulates D1 and D2 receptors leading to vasodilation, 
decreased arterial blood pressure, and increased renal and splanchnic 
vascular blood flow. Diuresis and natriuresis also occur. The decrease 
in diastolic blood pressure might lead to a reflex increase in heart rate. 
At higher infusion rates (3 to 10 µg/kg/minute), dopamine 
primarily stimulates β1-adrenergic receptors in the heart as well as α 
receptors in the peripheral vasculature. It also induces norepinephrine 
release from vascular sympathetic neurons. The activation of β 
receptors leads to increased cardiac output by increasing chronotropy 
and contractility along with vasodilation and afterload reduction. 
As the infusion rate is increased even further (>10 µg/kg/minute), 
dopamine predominantly stimulates α1 receptors, acting similarly to a 
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pure α agonist. The predominant stimulation of vascular smooth 
muscle α1 receptors at these higher doses lead to arterial and venous 
vasoconstriction, increased systemic vascular resistance, and increased 
blood pressure attenuating further increases in cardiac output. Reflex 
bradycardia may also occur at this point. 
This aforementioned dose-dependent model of dopamine’s effects 
is too simplistic, even in healthy individuals. There are a wide range of 
clinical responses depending on individual variability in 
pharmacokinetics as well as other variables. 
For example, despite identical IV infusion rates, there may be a 
10- to 75-fold variability in plasma dopamine concentrations produced 
even in healthy individuals with normal drug metabolism. The 
etiology of the wide pharmacokinetic variability and variation in 
individual responses is likely multifactorial, reflecting differences in 
drug distribution, elimination, and endogenous levels, among other 
factors. Such differences may be even more profound in critically ill 
patients. Hence, the effects of dopamine cannot be predicted based on 
the dose, and the drug must be titrated to effect. 
Dopamine increases cardiac output by stimulation of β1 receptors, 
increasing stroke volume. This increase in cardiac output is usually 
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accompanied by only modest increases in heart rate, systemic blood 
pressure, and systemic vascular resistance. A portion of the effect of 
dopamine is also due to stimulation of endogenous norepinephrine 
release, which may predispose to the development of cardiac 
dysrhythmias. Nevertheless, dopamine is less dysrhythmogenic than 
epinephrine. The release of norepinephrine caused by dopamine may 
be an unreliable mechanism for increasing cardiac output when 
catecholamine stores are depleted, as occurs with patients in chronic 
cardiac failure.  
Dopamine increases myocardial oxygen consumption.Dopamine 
causes both relaxation and contraction of vascular smooth muscle with 
the predominant effect varying by vascular bed, predominant receptor 
type, and dose administered. Dopamine’s effect on pulmonary 
vascular resistance has not been well studied in humans, though there 
are some reports it may decrease pulmonary vascular resistance in 
patients with chronic obstructive pulmonary disease. 
Rapid metabolism of dopamine with an elimination half-life of 1 
to 2 minutes mandates its use as a continuous infusion (1 to 20 
µg/kg/minute) to maintain therapeutic plasma concentrations. 
Dopamine should be dissolved in 5% glucose in water for IV 
administration to avoid the inactivation that may occur in alkaline 
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solutions. Extravasation of dopamine, like norepinephrine, produces 
intense local vasoconstriction, which may be treated with local 
infiltration of phentolamine. 
Dopamine is not effective orally and does not cross the 
blood–brain barrier in sufficient amounts to cause CNS effects. The 
immediate precursor of dopamine, L-dopa, is absorbed from the 
gastrointestinal tract and readily crosses the blood–brain barrier. 
Dopamine is partially protein bound. Approximately 25% is converted 
to norepinephrine. Dopamine undergoes metabolism in the liver with 
conjugation to sulfates and glucuronides, pulmonary endothelium by 
catechol-O-methyltransferase (COMT) and excretion by the kidneys. 
Clinical Uses 
Dopamine is used clinically to increase cardiac output in patients 
with decreased contractility, low systemic blood pressure, and low 
urine output as may be present after cardiopulmonary bypass or with 
chronic heart failure. It is unique among the catecholamines in being 
able to simultaneously increase myocardial contractility, renal blood 
flow, glomerular filtration rate, excretion of sodium and urine output.  
Dopamine exerts its positive chronotropic, dromotropic, inotropic, 
and lusitropic (myocardial relaxant) effects via β1-adrenergic 
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receptors. Activation of arterial and venous α1 receptors increases 
systemic vascular resistance, preload, and left ventricular 
afterload.However, as dopamine increases pulmonary vascular 
resistance as well, it may not be the preferred inotropic agents in 
patients with pulmonary hypertension or right ventricular dysfunction. 
Renal-Dose Dopamine 
The term renal-dose dopamine or low-dose dopamine refers to the 
continuous infusion of small doses (1 to 3 µg/kg/minute) of dopamine 
to patients to promote renal blood flow. In healthy individuals, 
low-dose dopamine increases renal blood flow and induces natriuresis 
and diuresis Theoretically, dopamine’s renal vasodilating effects may 
be useful in patients with impaired renal function or in patients at risk 
of decreased renal perfusion as may occur with decreased cardiac 
output.  
Small doses of dopamine increase renal blood flow predominantly 
by D1 receptors in the renal vasculature and possibly by D2 receptors 
via inhibition of norepinephrine release. Larger doses predominantly 
increase renal blood flow by β-adrenergic–mediated increases in 
cardiac output. Higher doses of dopamine presumably stimulate α 
receptors to increase perfusion pressure. In addition, dopamine 
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triggers natriuresis and diuresis through direct effect on tubular cell 
function. Dopamine binds to D1 and D2 receptors in the proximal 
tubule, thick ascending loop of Henle, and cortical collecting ducts 
inhibiting sodium-potassium ATPase activity, increasing sodium 
excretion, inducing natriuresis and diuresis. 
The activation of D2 in inner medullary collecting ducts stimulates 
prostaglandin E2 production. This antagonizes the effects of 
antidiuretic hormone and results in increased free water clearance. 
PGE2 enhances blood flow in the inner medulla. Inhibition of 
aldosterone also increases sodium excretion and diuresis. Hence, 
dopamine has direct and indirect effects on the renal vasculature in 
addition to functioning as a diuretic. 
The term renal-dose or low-dose dopamine is misleading as 
dopamine has many effects at sites other than the kidneys, even at low 
doses. Dopamine’s effects based on dose alone are unpredictable. 
Low-dose dopamine also implies an unproven beneficial effect on 
renal function.In patients receiving dopamine before a “renal insult,” 
there is a clear diuretic effect but none for improved creatinine 
clearance or decreased need for hemodialysis.Despite drug-induced 
diuresis, there is no evidence that urine output in the presence of low 
cardiac output and/or hypovolemia protects renal function. The use of 
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dopamine after the renal insult has occurred has not been shown to 
improve glomerular filtration rate. There is evidence that the 
beneficial effect of low-dose dopamine on renal blood flow and 
glomerular filtration rate observed in healthy individuals is due to 
drug-induced increases in cardiac output, and this benefit is lost in 
early renal failure.  
No randomized controlled studies have demonstrated a decrease in 
the incidence of acute renal failure when dopamine is administered to 
patients considered to be at risk for developing acute renal failure in 
multiple patient populations (major vascular surgery, cardiopulmonary 
bypass, intensive care, heart failure, sepsis, transplantation, patients 
exposed to nephrotoxic drugs) confirming the results of two large 
retrospective studies and two meta-analyses, finding that dopamine 
does not prevent or reverse acute renal failure or improve outcome. 
Aside from one study demonstrating dopamine selectively increases 
renal blood flow in heart failure patients via dilation of both large 
conductance and small resistance renal blood vessels, there exists no 
proven improvement in renal perfusion, creatinine clearance, or 
glomerular filtration rate and no alteration in the course of renal 
failure or the need for renal replacement therapy. 
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Dopamine leads to an increase in cortical and inner medullary 
blood flow, shunting flow from the outer medulla. It increases solute 
delivery to the distal tubular cells increasing medullary oxygen 
consumption. The outer medulla is highly metabolically active and 
highly  
susceptible to ischemic injury and acute renal failure. Dopamine can 
induce renal failure in both normo- and hypovolemic patients. 
Low-dose dopamine is associated with multiple complications 
affecting the cardiovascular, pulmonary, gastrointestinal, endocrine, 
and immune systems.  
Cardiovascular Effects 
Dopamine is associated more than dobutamine or epinephrine with 
dose-related sinus tachycardia and the potential to cause ventricular 
arrhythmias and may predispose to myocardial ischemia by 
precipitating tachycardia, increasing contractility, increasing afterload, 
and precipitating coronary artery vasospasm. Dopamine increases 
peripheral vascular resistance and pulmonary artery pressures. Unlike 
dobutamine, dopamine does not inhibit hypoxic pulmonary 
vasoconstriction. Nevertheless, dopamine is not recommended for use 
in right heart failure. 
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Gastrointestinal Effects 
Gastrointestinal mucosal ischemia and subsequent translocation of 
bacteria and bacterial toxins play an important role in the development 
of multiple organ dysfunction syndrome. Dopamine’s effect on 
splanchnic blood flow and gastric intramucosal pH is controversial 
and inconsistent. There is no evidence that low-dose dopamine has 
beneficial effects on splanchnic function or reduces the progression to 
multiorgan failure in sepsis. Dopamine may increase flow to the 
muscular layer of the gut with decreased flow to the mucosal layer 
with detrimental effects and possibly gut ischemia. In septic patients, 
dopamine but not norepinephrine, as administered to maintain an 
acceptable mean arterial pressure, resulted in an uncompensated 
increase in splanchnic oxygen requirements. Although dopamine 
infusion in septic patients led to increased hepatosplanchnic perfusion, 
hepatosplanchnic oxygen uptake was reduced suggesting an 
impairment of hepatosplanchnic metabolism.Most of these studies 
have looked at the effects of low-dose dopamine rather than doses 
used to treat hypotension. 
D2 receptors are also located in the enteric nervous system. 
Dopamine agonists interfere with gastrointestinal motility. Low-dose 
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dopamine has been demonstrated to slow gastric motility in 
mechanically ventilated intensive care patients. 
Endocrine and Immunologic Effects 
Dopamine disrupts metabolic and immunologic functions through 
its effects on hormones and lymphocyte function. The anterior 
pituitary plays a crucial role in metabolic and immunologic 
homeostasis. The initial stress response stimulates pituitary hormone 
release, whereas the chronic phase is associated with suppression of 
the hypothalamic-pituitary axis. In the acute phase of an illness, 
dopamine induces the pattern of hypopituitarism seen in prolonged 
critical illness and chronic stress. When dopamine is used in the 
chronic phase of illness, it further suppresses the circulating 
concentrations of pituitary hormones. 
Dopamine depresses the immune status by reducing serum 
prolactin levels. Prolactin is an immunoregulatory hormone affecting 
T and B lymphocytes. Dopamine inhibits lymphocyte proliferation, 
immunoglobulin synthesis, and cytokine production and promotes 
lymphocyte apoptosis. Dopamine also decreases the secretion of 
growth hormone, which has anabolic, lipolytic, and 
immune-stimulating properties. Growth hormone deficiency can 
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contribute to impaired anabolism and a negative nitrogen balance. 
Dopamine’s inhibition of thyrotropin-releasing hormone leads to 
“euthyroid sick syndrome.” It also decreases dehydro-epiandrosterone 
sulfate and may affect luteinizing hormone release. Dopamine’s 
overall effect is to suppress the secretion and function of anterior 
pituitary hormones, aggravating catabolism and cellular immune 
function and inducing central hypothyroidism. 
Respiratory Effects 
The infusion of low-dose dopamine in healthy subjects as well as 
heart failure patients interferes with the ventilatory response to arterial 
hypoxemia and hypercapnia, reflecting the role of dopamine as an 
inhibitory neurotransmitter at the carotid bodies.The result is 
depression of ventilation in patients who are being treated with 
dopamine to increase myocardial contractility. Dopamine also 
decreases arterial oxygen saturation by impairing regional 
ventilation/perfusion matching in the lungs. Dose-dependent 
reductions in arterial PO2 with increasing rates of dopamine in 
critically ill patients after major surgery have been demonstrated. 
Arterial blood gases have been observed to deteriorate during infusion 
of dopamine. 
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One study demonstrated low-dose dopamine did not influence 
ventilation specifically in patients with chronic obstructive pulmonary 
disease either breathing spontaneously or being weaned from 
mechanical ventilation. Dopamine may even decrease pulmonary 
vascular resistance in patients with chronic obstructive pulmonary 
disease. Other potential beneficial effects are improved respiratory 
muscle contraction, increased lung edema clearance, and inhibition of 
bronchoconstriction. However, such reports are anecdotal or not tested 
in clinical studies. 
Intraocular Pressure 
Continuous infusions of dopamine to critically ill patients are 
associated with increases in intraocular pressure.This may create a risk 
in patients with preexisting glaucoma especially if they are sedated 
and mechanically ventilated. 
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PHARMACEUTICAL INFORMATION  
 
 Proper name:  Dopamine Hydrochloride   
 Chemical name:  3,4-dihydroxyphenethylamine hydrochloride   
 Molecular formula: C8H11NO2  
 Molecular mass: 189.64   
Structural formula:        
Physicochemical properties:  Dopamine hydrochloride is a white, 
odorless, crystalline powder, soluble in water and alcohol with a 
melting point range of 240° to 248°C (with decomposition).  It is 
sensitive to light, alkalis, iron salts and oxidizing agents.    
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Synthetic Noncatecholamines 
The commonly used noncatecholamine sympathomimetic drugs 
are ephedrine and phenylephrine. 
 Ephedrine31 
 
Ephedrine is an indirect-acting synthetic sympathomimetic that 
stimulates α- and β-adrenergic receptors. It is the active principle of 
the Chinese plant Ma Huang, used for centuries in the East. It was first 
brought to Europe in 1923 and it is now produced synthetically.The 
pharmacologic effects of ephedrine are partly due to direct stimulation 
of adrenergic receptors (direct-acting) and partly due to stimulation of 
release of endogenous norepinephrine (indirect-acting). Ephedrine is 
resistant to metabolism by monoamine oxidase (MAO) in the 
gastrointestinal tract, thus permitting unchanged drug to be absorbed 
into the circulation after oral administration. Structurally it has two 
asymmetrical carbon atoms: only l-ephedrine and racemic ephedrine 
are used clinically.Intramuscular injection of ephedrine is clinically 
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acceptable because drug-induced local vasoconstriction is insufficient 
to delay systemic absorption or lead to tissue injury. 
Up to 40% of a single dose of ephedrine is excreted unchanged in 
urine. Some ephedrine is deaminated by MAO in the liver, and hepatic 
conjugation also occurs. The slow inactivation and excretion of 
ephedrine are responsible for the prolonged duration of action of this 
sympathomimetic. 
Ephedrine, unlike epinephrine, does not produce marked 
hyperglycemia. Mydriasis accompanies the administration of 
ephedrine, and CNS stimulation does occur, although less than that 
produced by amphetamine.Myocardial irritability is increased, which 
may produce arrhythmias. Other actions include a reduction in 
cerebral and renal blood flow, bronchodilation (hence its use in 
treating asthma), increase in sphincter tone (which may lead to urinary 
retention).  
Clinical Uses 
Ephedrine, 5 to 10 mg IV administered to adults, is a commonly 
selected sympathomimetic to increase systemic blood pressure in the 
presence of sympathetic nervous system blockade produced by 
regional anesthesia or hypotension due to inhaled or injected 
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anesthetics. In an animal model, ephedrine more specifically corrected 
the noncardiac circulatory changes produced by spinal anesthesia than 
did a selective α or β agonist drug. 
Until recently, ephedrine was considered the preferred 
sympathomimetic for administration to parturients experiencing 
decreased systemic blood pressure owing to spinal or epidural 
anesthesia. Support for this practice was the observation in pregnant 
ewes that uterine blood flow was not greatly altered when ephedrine 
was administered to restore maternal blood pressure to normal after 
production of sympathetic nervous system blockade. Recent reviews 
of trials of ephedrine versus phenylephrine have concluded that 
systemic blood pressure control is similar with both drugs but 
phenylephrine is associated with a higher umbilical artery pH at 
delivery than ephedrine.  
Administration of phenylephrine by infusion during cesarean 
section to maintain maternal systolic blood pressure at baseline is 
associated with a lower incidence of fetal acidosis than is ephedrine. 
Based on these data, it seems that α agonists such as phenylephrine 
may be preferable to ephedrine for treatment of maternal hypotension. 
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Ephedrine can be used as chronic oral medication to treat 
bronchial asthma because of its bronchodilating effects by activation 
of β2-adrenergic receptors. Compared with epinephrine, the onset of 
action of ephedrine is slow, becoming complete only 1 hour or more 
after administration. A decongestant effect accompanying oral 
administration of ephedrine produces symptomatic relief from acute 
coryza. Ephedrine, 0.5 mg/kg intramuscularly, has an antiemetic effect 
similar to that of droperidol but with less sedation when administered 
to patients undergoing outpatient laparoscopy using general 
anesthesia. 
Cardiovascular Effects 
The cardiovascular effects of ephedrine resemble those of 
epinephrine, but its systemic blood pressure–elevating response is less 
intense and lasts approximately 10 times longer. Intravenous 
ephedrine results in increases in systolic and diastolic blood pressure, 
heart rate, and cardiac output. Renal and splanchnic blood flows are 
decreased, whereas coronary and skeletal muscle blood flows are 
increased. Systemic vascular resistance may be altered minimally 
because vasoconstriction in some vascular beds is offset by 
vasodilation (β2 stimulation) in other areas. These cardiovascular 
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effects are due, in part, to α receptor–mediated peripheral arterial and 
venous vasoconstriction.  
The principal mechanism, however, for cardiovascular effects 
produced by ephedrine is increased myocardial contractility due to 
activation of β1 receptors. In the presence of preexisting β-adrenergic 
blockade, the cardiovascular effects of ephedrine may resemble 
responses more typical of α-adrenergic receptor stimulation. 
A second dose of ephedrine produces a less intense systemic blood 
pressure response than the first dose. This phenomenon, known as 
tachyphylaxis, occurs with many sympathomimetics. Tachyphylaxis to 
ephedrine appears to involve α receptor inhibition. 
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REVIEW OF LITERATURE 
 
1. Cabalum  et al 197932 studied the Effects of dopamine on 
hypotension induced by spinal anesthesia and found that 
chronically instrumented, near-term pregnant sheep were subjected 
to autonomic blockade with spinal anesthesia. Systemic arterial 
pressure, heart rate, and uterine blood flow decreased and uterine 
vascular resistance increased during the spinal blockade. Infusion 
of dopamine during the spinal hypotension corrected the disturbed 
circulatory parameters. Dopamine represents a useful agent in the 
management of spinal hypotension. 
2. Clark RB et al 33found that Dopamine has been shown to decrease 
uterine blood flow in animals, and has not been shown to have any 
benefit over ephedrine in humans.  
3. Butterworth et al34 found that acute denervation of spinal 
anesthesia altered venous and arterial dose-response relationships 
of both dopamine and dobutamine. Their study demonstrates the 
effectiveness of dobutamine and, perhaps even more so, dopamine 
as possible alternatives to ephedrine for the pharmacologic 
correction of the non cardiac circulatory sequelae of spinal 
anesthesia. 
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4. Lundberg et al35 found that myocardial contractility and arterial 
pressure were restored to pre-Thoracic Epidural Analgesia values 
by dopamine at 5–10 μg · kg-1 · min-1. 
5. Toshiharu Kasaba et al36found that Dopamine is preferable to 
ephedrine and dobutamine in providing hemodynamic stability 
during propofol induction and tracheal intubation following 
epidural anesthesia. 
6. J.F.Lundberg et al37 found that the systemic pressure response 
induced by dopamine was augmented during epidural anesthesia. 
Norepinephrine did not increase arterial pressure and myocardial 
contractility as markedly as dopamine, and cardiac output was not 
altered.  
7. Rolbin SH et al38  found that treatment of spinal hypotension 
with dopamine decreases uterine blood flow in the pregnant 
ewe/animals, and has not been shown to have any benefit over 
ephedrine in humans. 
8. Defeng Sun et al39 found that dopamine can be used to correct 
epidural anesthesia-induced hypotension and compared the effects 
of methoxamine versus dopamine on the hemodynamic 
parameters.Their findings suggest that methoxamine can have an 
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effect similar to that of dopamine in controlling hemodynamic 
stability, but it is superior to dopamine in reducing the risk of a 
tachycardia-induced increase in myocardial oxygen consumption 
in elderly patients. 
9. Ward RJ, Kennedy WF Jr, Bonica JJ, Martin WE, Tolas AG, 
Akamatsu T.et al40 Did experimental evaluation of atropine and 
vasopressors for the treatment of hypotension of high 
subarachnoid anesthesia and found that atropine is not useful for 
spinal hypotension and ephedrine is a better option for spinal 
hypotension. 
10. Butterworth JF IV, Piccione W Jr, Berrizbeitia LD, Dance G, 
Shemin RJ, Cohn LH.et al41 Studied on augmentation of venous 
return of leg using adrenergic agonists during spinal anesthesia 
and concluded that a mixed adrenergic agonist such as ephedrine 
more ideally corrects the noncardiac circulatory sequelae of spinal 
anesthesia than does either a pure [alpha]-or [beta]-adrenergic 
agonist. 
11. Nygan Kee WD, Khaw KS, Ng FF, Lee BB.et al42Did a study on 
Prophylactic phenylephrine infusion for preventing hypotension 
during spinal anesthesia for cesarean delivery and found that 
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prophylactic phenylephrine infusion is a simple, safe, and effective 
method of maintaining arterial blood pressure during spinal 
anesthesia for cesarean delivery. 
12. Frazer RS Edwards GM. et al43Did a study using prophylactic 
ephedrine infusion in obstetric anaesthesia and concluded that 
prophylactic ephedrine should be used in obstetric as well as in 
other cases of spinal anaesthesia to prevent hypotension. 
13. Kang YG, Abouleish E, Caritis S. et al44Studied about 
prophylactic intravenous ephedrine infusion during spinal 
anesthesia for cesarean section and The results suggest that 
prophylactic ephedrine infusion is safe and desirable in healthy 
parturients undergoing cesarean section under spinal anesthesia.  
14. Gajraj NM, Victory RA, Pace NA, Van Elstraete AC, Wallace 
DH.et al45 Did a comparison of an ephedrine infusion with 
crystalloid administration for prevention of hypotension during 
spinal anesthesia and concluded that a prophylactic ephedrine 
infusion is effective for minimizing and managing hypotension 
associated with spinal anesthesia and compares favorably with 
crystalloid administration in this patient population in terms of 
efficacy and incidence of side effects. 
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15. Hemmingsen C, Poulsen JA, Risbo A. Et al46Did a double-blind 
study using prophylactic ephedrine during spinal anaesthesia in 
patients in ASA groups I–III and concluded that prophylactic 
ephedrine is desirable for spinal anaesthesia, especially in ASA III 
patients. 
16. RS Emmett, AM Cyna, M Andrew, SW Simmons et al47did a 
cochrane review on techniques for preventing hypotension during 
spinal anaesthesia for caesarean section and concluded that no 
intervention reliably prevents hypotension during spinal 
anaesthesia for caesarean section. No conclusions are drawn 
regarding rare adverse effects of interventions due to their 
probable low incidence and the small numbers of women studied. 
Further trials are recommended, in particular assessing a 
combination of the beneficial interventions, ie colloid or 
crystalloid preloading, ephedrine administration and leg 
compression with bandages, stockings or inflatable boots. 
17. Coe AJ, Revanäs B. Et al48 did a study ;Is crystalloid preloading 
useful in spinal anaesthesia in the elderly? And concluded that 
Crystalloid preloading had no effect on the incidence of 
hypotension after spinal anaesthesia in fit, elderly patients. 
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18. Engberg G, Wiklund L.et al49 Did a study on the use of 
subcutaneous ephedrine premedication for prevention of arterial 
hypotension during epidural blockade and concluded that 
ephedrine premeditation prevented marked hypotension following 
epidural blockade in all groups, the pressor effect being most 
pronounccd when adrenaline was included in the local anaesthetic 
solution. 
19. W. S. Chan et al50 did a study on prevention of hypotension 
during spinal anaesthesia for caesarean section: ephedrine infusion 
versus fluid preload and concluded that  prophylactic ephedrine 
infusion alone is at least as good as fluid preload alone in 
combating the hypotension associated with spinal anaesthesia for 
caesarean section. 
20. R.JACKSON et al51 did a comparison study on volume pre 
loading and prophylactic ephedrine infusion and concluded that 
volume preloading is not essential to prevent spinal induced 
hypotension in caesarean section. 
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AIM OF THE STUDY 
To study the effects of various doses of dopamine as continuous 
intravenous infusion on the intraoperative hemodynamics in patients 
undergoing elective surgeries under spinal anaesthesia and to decide 
about the appropriate dose of dopamine needed to prevent hypotension 
in patients undergoing surgeries under spinal anaesthesia. 
PRIMARY OBJECTIVE 
To compare the various parameters observed during infusion of 
various doses of dopamine, like 
 Heart rate 
 Systolic blood pressure 
 Diastolic blood pressure 
 Mean arterial pressure 
SECONDARY OBJECTIVE 
To compare the Urine output in all 4 groups. 
 
 
 
 
 
  
45 
 
MATERIALS AND METHODS 
PATIENT SELECTION : 
After getting approval from the Ethical committee of Govt.Kilpauk 
medical college and getting written informed consent from 
patients/relatives,120 patients of ASA I & II who underwent elective 
surgeries under spinal anaesthesia at Government Kilpauk Medical College 
Hospital and Government Royapettah Hospital, were enrolled in this study 
group. 
 INCLUSION CRITERIA 
 Patients of age between 25 to 65years 
 height >150cm and <170cm, 
 weight 40-75kg 
 Patients undergoing elective surgeries under spinal anaesthesia 
requiring sensory blockade level of T6 and below 
 ASA I & ASA II 
 Consent from patient. 
 EXCLUSION CRITERIA 
 ASAIII & ASA IV 
 Patients who are known allergic to study drugs 
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 Patients having contraindications for spinal anaesthesia 
 Emergency surgeries 
 Valvular heart disease 
 Ischaemic heart disease 
 Hypertension 
 Metabolic disorders 
 Anaemic patient 
 Prolonged surgeries for more than 2 hours 
 Surgeries requiring sensory blockade above T6 
 Surgeries causing major fluid shifts/blood loss >10% of 
blood volume 
 Surgeries requiring other than supine position 
 severe liver or kidney insufficiency 
 history of hyperthyroidism/hypothyroidism 
 recent administration of tricyclic antidepressants or 
monoamine oxidase inhibitors 
 History of type2 DM >5yrs 
 Patients not willing to take part in study 
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GROUPS : 
a. Group A :30 patients who do not receive dopamine infusion 
during surgery 
b. Group B : 30 patients who receive continuous intravenous 
Dopamine  infusion @3mcg/kg/minute 
c. Group C : 30 patients who receive continuous intravenous  
Dopamine infusion @5mcg/kg/minute 
d. Group D : 30 patients who receive continuous intravenous  
Dopamine infusion @7mcg/kg/minute 
 
METHODOLOGY : 
This study was designed as a randomized control 
study.Patients were preoperatively evaluated,clinically 
examined and proper investigations were done prior to 
assessment. Procedure was explained in detail and written 
consent was obtained. After ascertaining the inclusion 
criteria,preoperative investigations were recorded. 
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Anesthesia procedure 
The procedure was carried out in the theatre where facilities 
for resuscitation were available. All patients were deprived of 
food for overnight before surgery.Patients were randomly 
selected and divided into Group A, GroupB, Group C and 
Group D to receive intravenous dopamine infusion @ 0, 3, 5, 
and 7 mcg/kg/minute respectively.  Intravenous cannulation 
was carried out with 18G venflon.All patients in four groups 
received inj.midazolam 2mg and inj.ondansetron 4mg 
intramuscularly half an hour prior to shifting to operating 
room.All the patients were preloaded with 15ml/kg of 
ringerlactate solution  half an hour prior to subjecting to spinal 
anaesthesia.Vitals such as BP, Pulse, Respiratory rate, SPO2 
were measured before the patient is being shifted to operating 
room. After shifting to operating room all the patients were 
subjected to spinal anaesthesia in lateral decubitus position, 
under sterile aseptic precautions using 25G QUINKE’S needle 
at L3-L4 space and 3.5ml of 0.5% bupivacaine[ heavy] was 
given.  
Intraoperatively group A, B,Cand D patients received dopamine 
infusion @0,3,5,7 mcg/kg/minute respectively soon after positioning the 
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patient. Level of sensory blockade checked at 5 minutes after sub 
arachnoid block.All the 4 group patients received crystalloid infusion 
intraoperatively @ 10ml/kg/hr.If any patients in group A,B,C,D had 
Hypotension (defined as a decrease in systolic arterial pressure (SAP) more 
than 20% below baseline and to below 100 mm Hg)  intraoperatively,they 
received incremental doses of ephedrine(6mg) iv bolus as required. 
Anesthesia monitoring 
Pulse rate, blood pressure,mean arterial pressure, ECG, SpO2  were 
recorded at varying intervals[T1(1st minute),T2(2nd minute),T3,T4,T5]then 
every 5 minutes upto 30 minutes, then every 10 minutes till the end of the 
surgery. Urine output was measured every 60 minutes.Then the data were 
collected and analysed. 
The parameters studied are 
1. Systolic pressure 
2. Diastolic pressure 
3. Mean arterial pressure 
4. heart rate 
5. Urine output 
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Monitors used 
 Pulse oximetry 
 NIBP(Arterial blood pressure was measured by oscillometric method ) 
 ECG(3 LEAD ECG ) 
Data analysis  
Statistical analyses were performed using SPSS 23.0 (SPSS Inc., 
IBM,Chicago, IL, USA). Sample size estimation was determined by 
power analysis with one-way analysis of variance (ANOVA).sample 
size of 120 subjects (n=30 per group) was determined to be sufficient 
to detect differences in the means among the 4 groups, with a 
statistical power greater than 90%. All numerical values are presented 
as the mean and standard deviation (SD).  
  Repeated-measures ANOVA was used to compare differences 
within the same group. One-way ANOVA was used to compare 
differences among groups. Categorical data were compared by the 
chi-squared test. Differences with p<0.05 were considered to be 
statistically significant. 
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OBSERVATION AND RESULTS 
 
 A total of 120 patients of ASA- PS1/PS2 were studied in this 
study. 
 Thirty patients were enrolled into each of the four groups (A,B,C 
and D). 
 There was no statistical significance between the four groups when 
the demographic parameters like age distribution, sex 
distribution,weight and height of the patients and ASA status 
classification were compared. 
 The comparison of parameters like, pre operative systolic blood 
pressure, diastolic blood pressure , mean arterial pressure,and heart 
rate was also found to be statistically insignificant between the 
four groups.  
 Sensory blockade level was also comparable between all groups 
and statistically insignificant. 
 All the 120 patients underwent similar procedures which lasted for 
less than 120 minutes with insignificant blood loss. 
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GENDER DISTRIBUTION  
Gender GROUP-A GROUP-B GROUP-C GROUP-D 
N % N % N % N % 
MALE 3 10.00 3 10.00 4 13.33 3 10.00 
FEMALE 27 90.00 27 90.00 26 86.67 27 90.00 
TOTAL 30 100 30 100 30 100 30 100 
 
  
53 
 
 
 
 
AGE GROUP 
Age Group GROUP-A GROUP-B GROUP-C GROUP-D 
N % N % N % N % 
25 - 35 6 20.00 6 20.00 7 23.33 6 20.00 
36 - 45 10 33.33 10 33.33 3 10.00 8 26.66 
46 - 55 4 13.34 5 16.67 9 30.00 5 16.67 
56 - 65 10 33.33 9 30.00 11 36.67 11 36.67 
TOTAL 30 100 30 100 30 100 30 100 
Mean 47.60 46.77 48.10 47.83 
SD 13.19 12.91 14.11 13.27 
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Height Distribution 
Height (in 
Cms) 
GROUP-A GROUP-B GROUP-C GROUP-D 
N % N % N % N % 
150 - 155 3 10.0
0 
5 16.67 5 16.6
7 
3 10.0
0 
156 -160 6 20.0
0 
7 23.33 5 16.6
7 
5 16.6
7 
161 - 165 11 36.6
7 
10 33.33 10 33.3
3 
12 40.0
0 
166 - 170 10 33.3
3 
8 26.67 10 33.3
3 
10 33.3
3 
TOTAL 30 100 30 100 30 100 30 100 
Mean  163.23 161.57 163.13 163.27 
SD 5.22 5.39 5.31 5.05 
T-value                 
Group A vs 
 1.22 0.07 0.03 
p-value  0.23 0.94 0.98 
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Weight in Kg GROUP-A GROUP-B GROUP-C GROUP-D 
N % N % N % N % 
40 - 45 1 3.33 1 3.33 0 0.00 1 3.33 
46 - 50 2 6.67 2 6.67 9 30.00 3 10.00 
51 - 55 6 20.00 8 26.67 4 13.33 5 16.67 
56 - 60 11 36.67 9 30.00 4 13.33 11 36.67 
61 - 65 3 10.00 6 20.00 8 26.67 3 10.00 
66 - 70 6 20.00 4 13.33 5 16.67 6 20.00 
71 - 75 1 3.33 0 0.00 0 0.00 1 3.33 
TOTAL 30 100 30 100 30 100 30 100 
Mean 59.30 58.20 58.33 59.57 
SD 6.95 6.01 6.87 7.26 
t-value               
Group A vs 
 0.66 0.54 0.15 
p-value  0.52 0.59 0.89 
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ASA-PS STATUS 
ASA GROUP-A GROUP-B GROUP-C GROUP-D 
N % N % N % N % 
PS1 16 53.33 18 60.00 13 43.33 17 56.67 
PS2 14 46.67 12 40.00 17 56.67 13 43.33 
TOTAL 30 100 30 100 30 100 30 100 
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Diagnosis GROUP-A GROUP-B GROUP-C GROUP-D 
N % N % N % N % 
B/L inguinal 
Hernia 
1 3.33 0 0 0 0 3 10.0
0 
Incisional 
Herina 
2 6.66 1 3.33 0 0 1 3.33 
Lt inguinal 
Herina 
12 40.00 10 33.3
3 
4 13.3
3 
15 50.0
0 
Rt inguinal 
Herina 
14 46.67 17 56.6
7 
21 70.0
0 
9 30.0
0 
Umblical 
Herina 
1 3.33 2 6.67 5 16.6
7 
2 6.67 
TOTAL 30 100 30 100 30 100 30 100 
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Systolic Blood Pressure  
 GROUP-A GROUP-B GROUP-C GROUP-D Significance (p value) 
Mean± 
SD 
Mean± 
SD 
Mean± 
SD 
Mean± 
SD 
A vs B A vs C A vs D 
Pre 
op 
126.27±13
.92  
128.30±06
.94 
125.10±11
.03  
126.13±11
.41  
*0.48 *0.72 *0.96 
T1 126.90±15
.01  
122.33±05
.90 
127.27±10
.68  
116.57±16
.48  
*0.13 *0.91 0.01 
T2 114.60±19
.82 
114.50±10
.47 
129.17±11
.56 
114.00±17
.17 
*0.98 0.0001 *0.90 
T3 109.57±18
.81  
111.47±12
.36  
133.33±15
.43 
119.87±19
.56  
*0.65 0.0001 0.04 
T4 109.57±18
.81  
111.47±12
.36  
133.33±15
.43 
119.87±19
.56  
*0.62 0.0001 0.02 
T5 108.20±15
.12  
105.20±14
.92  
128.77±12
.76 
123.20±23
.15 
*0.44 0.0001 0.004 
T10 109.73±15
.59  
103.90±16
.12 
127.30±13
.61 
124.77±20
.84 
*0.16 0.0001 0.002 
T15 108.67±14
.26 
109.03±11
.60 
123.67±12
.06 
124.60±19
.91 
*0.91 0.0001 0.001 
T20 109.70±12
.69 
110.27±12
.86 
124.87±11
.11 
126.70±22
.47 
*0.86 0.0001 0.001 
T25 107.80±13
.79 
109.70±12
.52 
125.37±14
.28 
136.50±25
.97 
*0.58 0.0001 0.0001 
T30 108.97±13
.83 
112.87±11
.46 
121.43±14
.09 
133.23±21
.34 
*0.24 0.001 0.0001 
T40 108.13±14
.35 
114.70±11
.11 
124.47±12
.13 
128.23±15
.01 
0.05 0.0001 0.0001 
T50 110.90±14
.31 
115.40±10
.10 
126.90±13
.17 
127.80±13
.69 
*0.17 0.0001 0.0001 
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T60 112.40±14
.24 
114.23± 
9.22 
127.33±12
.08 
125.73± 
6.57 
*0.56 0.0001 0.0001 
T70 105.26±22
.70 
117.90±11
.91 
124.93±14
.51 
120.50± 
5.13 
0.01 0.0001 0.001 
T80 112.80±13
.03 
119.73± 
9.04 
124.77±13
.72 
123.10± 
3.48 
0.02 0.002 0.0001 
T90 111.05±12
.52 
119.47± 
8.36 
124.96±  
9.09 
120.13± 
2.16 
0.01 0.0001 0.0001 
T100 115.53±13
.06 
121.37± 
4.44 
122.29±  
8.31 
119.63± 
4.86 
*0.08 *0.08 *0.13 
* Not Significant 
 
 When systolic blood pressure was compared between group A 
and the other 3 groups,there was significant statistical difference 
between group A and C, A and D,from T2 to T90 minutes. 
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Diastolic Blood Pressure  
 GROUP-A GROUP-B GROUP-C GROUP-D Significance 
Mean± 
SD 
Mean± 
SD 
Mean± 
SD 
Mean± 
SD 
A vs 
B 
A vs 
C 
A vs 
D 
Pre 
op 
84.63± 
9.07 
82.53± 
2.43 
83.07± 
4.46  
81.76± 
8.40 
*0.23 *0.40 *0.21 
T1 79.70± 
9.52 
78.13± 
2.89 
81.13±10.
58  
74.43±16.
58 
*0.39 *0.58 *0.14 
T2 72.37±12.
45 
72.23± 
7.20 
77.83± 
9.25 
71.33±16.
85 
*0.96 *0.06 *0.79 
T3 69.43±10.
48 
68.67± 
8.97 
79.97± 
9.74 
74.93±14.
76 
*0.76 0.000
1 
*0.10 
T4 70.67±11.
80 
67.50±10.
20 
76.23± 
9.80 
75.83±14.
77 
*0.27 0.05 *0.14 
T5 69.47±10.
49 
65.20±12.
66 
74.60±10.
99 
69.73±16.
27 
*0.16 *0.07 *0.94 
T10 69.00±10.
69 
65.57±11.
06 
74.53± 
9.73 
71.27±14.
55 
*0.23 0.04 *0.49 
T15 68.33±11.
45 
70.63±12.
61 
72.87± 
8.59 
71.47±15.
04 
*0.46 *0.09 *0.37 
T20 69.73±10.
73 
69.23±10.
26 
73.90± 
8.16 
71.90±14.
61 
*0.85 *0.10 *0.52 
T25 68.03±10.
80 
67.57± 
6.68 
73.57±11.
02 
73.40±14.
33 
*0.84 0.05 *0.11 
T30 69.00±10.
58 
68.00± 
7.46 
71.97±11.
20 
73.67±14.
50 
*0.67 *0.30 *0.16 
T40 67.37±10.
36 
70.17± 
7.23 
71.60±11.
34 
70.83± 
9.82 
*0.23 *0.14 *0.19 
T50 69.30±11.
38 
71.83± 
6.81 
72.17± 
8.65 
70.30±11.
52 
*0.30 *0.28 *0.74 
T60 71.57±11.
29 
71.23±7.2
0 
73.03± 
9.21 
74.20±10.
64 
*0.89 *0.58 *0.36 
T70 73.37±11. 69.03±11. 70.20± 71.10± *0.15 *0.22 *0.37 
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10 26 7.99 7.78 
T80 71.84±10.
69 
72.53± 
6.24 
76.37± 
6.45 
73.73±8.0
9 
*0.77 *0.06 *0.46 
T90 70.95± 
9.61 
73.93± 
4.79 
75.35± 
4.69 
70.90± 
6.74 
*0.15 0.05 *0.98 
T100 72.94±10.
67 
78.79± 
7.74 
78.35± 
4.17 
73.43± 
4.69 
*0.07 *0.06 *0.83 
* Not Significant 
 When diastolic blood pressure of the control group was 
compared with the other three groups B,C and D there was no 
significant difference statistically. 
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Mean arterial Pressure  
 GROUP-A GROUP-B GROUP-C GROUP-D Significant 
Mean± 
SD 
Mean± 
SD 
Mean± 
SD 
Mean± 
SD 
A vs 
B 
A vs 
C 
A vs 
D 
Pre 
op 
102.33±9.
22  
101.40± 
5.65 
101.27±8.
46 
102.37± 
8.07 
*0.64 *0.64 *0.99 
T1 94.50± 
9.08 
92.13± 
4.09 
94.90± 
9.44 
86.70±16.
17 
*0.20 *0.87 0.03 
T2 85.60±14.
02 
84.80± 
8.43 
93.67± 
7.50 
88.43±15.
93  
*0.79 0.01 *0.47 
T3 82.67±12.
51 
82.13±10.
53 
96.67± 
8.25 
91.40±16.
26 
*0.86 0.000
1 
0.02 
T4 82.13±12.
88 
81.17±11.
29 
95.87± 
7.32 
89.20±16.
61 
*0.76 0.000
1 
*0.07 
T5 81.03±11.
28 
77.47±14.
02 
93.80± 
7.00 
85.87±18.
87 
*0.28 0.000
1 
*0.23 
T10 81.03±10.
16 
77.23±13.
71 
93.63± 
9.26 
88.27±16.
11 
*0.23 0.000
1 
0.04 
T15 80.87±10.
47 
83.87±14.
53 
89.90± 
8.13 
89.70±17.
89 
*0.36 0.000
1 
0.02 
T20 80.63±10.
16 
82.50±11.
22 
89.07± 
7.83 
91.20±21.
30 
*0.50 0.001 0.02 
T25 79.83±10.
78 
81.27± 
8.84 
92.13±10.
05 
94.70±19.
18 
*0.58 0.000
1 
0.000
1 
T30 80.80±10.
12 
82.27± 
8.67 
87.80± 
8.70 
94.80±17.
81 
*0.55 0.01 0.000
1 
T40 80.00±10.
54 
83.97± 
8.43 
89.43± 
7.33 
86.93±13.
78 
*0.11 0.000
1 
0.03 
T50 81.63±10.
79 
84.70± 
7.63 
90.23± 
7.20 
88.40±13.
35 
*0.21 0.001 *0.34 
T60 84.20±10.
44 
84.10± 
7.94 
92.30± 
6.95 
88.23± 
8.86 
*0.97 0.001 *0.11 
T70 80.89±12. 84.57±10. 88.23± 85.17± *0.24 0.01 *0.11 
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86 57 6.69 5.84 
T80   84.60± 
9.86 
85.77± 
8.10 
91.77± 
7.65 
88.57± 
5.71 
*0.63 0.01 *0.07 
T90 85.10±10.
39 
86.90± 
7.14 
94.46± 
7.81 
85.10± 
1.42 
*0.47 0.001 *1.00 
T100 87.59±11.
53 
90.68± 
8.08 
95.53± 
8.66 
86.47± 
1.14 
*0.35 0.03 *0.60 
* Not Significant 
 When mean arterial pressure of the three groups B,C and 
D,compared with control group A,there was statistically 
significant difference seen between the groups A and 
C(T2-T100),A and D(T3,T10-T40). 
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Heart Rate  
 GROUP-A GROUP-B GROUP-C GROUP-D Significant 
Mean± 
SD 
Mean± 
SD 
Mean± 
SD 
Mean± 
SD 
A vs 
B 
A vs 
C 
A vs 
D 
Pre 
op 
84.37±12.
36 
83.43±10.
01 
84.47± 
8.22 
80.43±11.
39 
*0.74 *0.97 *0.20 
T1 83.77±14.
21 
88.47± 
9.02 
86.03± 
8.77 
79.57±14.
04 
*0.13 *0.46 *0.25 
T2 81.67±15.
89 
88.20± 
6.55 
86.10± 
8.22 
72.93± 
8.66 
0.04 *0.18 0.01 
T3 80.53±15.
96 
80.60± 
6.44 
84.43±10.
99 
74.43± 
8.42 
*0.06 *0.28 *0.07 
T4 78.73±16.
05 
90.87± 
7.79 
83.83±13.
22 
75.60±10.
01 
0.000
1 
*0.18 *0.37 
T5 75.33±14.
43 
87.33± 
8.78 
80.43± 
8.92 
73.13± 
8.63 
0.000
1 
*0.11 *0.48 
T10 73.10±13.
62 
86.47±10.
52 
79.80±12.
91 
72.33±10.
23 
0.000
1 
*0.06 *0.81 
T15 71.67±12.
63 
80.50±10.
33 
78.63± 
9.55 
70.37±11.
40 
0.004 0.02 *0.68 
T20 70.33±12.
23 
75.00±12.
87 
74.43±12.
41 
70.83± 
9.65 
*0.16 *0.20 *0.86 
T25 68.40±10.
44 
74.20±13.
28 
72.13± 
7.53 
70.17± 
8.89 
*0.07 *0.12 *0.48 
T30 67.83± 
9.82 
74.23±14.
11 
74.27± 
9.17 
73.27± 
8.54 
0.05 0.01 0.03 
T40 66.20± 
9.56 
76.73±15.
16 
75.33± 
7.99 
70.53± 
8.51 
0.002 0.000
1 
*0.07 
T50 67.27± 
9.63 
74.17±12.
40 
73.00± 
7.41 
70.73± 
9.90 
0.02 0.01 *0.18 
T60 67.53±10.
21 
74.77±13.
41 
73.70± 
8.00 
74.60± 
8.91 
0.02 0.01 0.01 
T70 67.33±18. 77.00±13. 72.57± 72.93± 0.03 *0.15 *0.16 
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82 29 4.97 9.98 
T80 67.20±10.
34 
76.87±14.
18 
76.60± 
5.64 
73.10±11.
74 
0.01 0.000
1 
*0.06 
T90 65.80±10.
21 
76.07±11.
06 
76.08± 
5.54 
72.70± 
2.93 
0.002 0.000
1 
0.001 
T100 67.24±10.
42 
74.79±15.
24 
76.41± 
6.51 
79.17± 
9.25 
*0.10 0.004 0.000
1 
* Not Significant 
 When the heart rate of group A is compared with other three 
groups there was no consistent statistical difference till T30 in 
group A Vs C, A Vs D.But after T30 minutes there was significant 
fall in the heart rate in group A when compared to other 3 groups. 
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Ephedrine GROUP-A GROUP-B GROUP-C GROUP-D 
N % N % N % N % 
NO 6 20.00 20 66.66 29 96.66 30 100 
YES 24 80.00 10 33.33 1 3.33 0 0 
TOTAL 30 100 30 100 30 100 30 100 
 
 In group A 24 patients required ephedrine intravenous boluses.  
 In group B 10 patients required ephedrine intravenous  boluses. 
 In group C 1 patient and in group D none required ephedrine 
respectively. 
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EPHEDRINE DOSE 
Ephedrine 
Dose in mg 
GROUP-A GROUP-B GROUP-C GROUP-D 
N % N % N % N % 
0 6  20.
0 
20 66.66 29 96.66 30 100 
6 3 10.00 6 20.0 1 3.33 - - 
12 6 20.00 3 10.00 - - - - 
18 11 36.67 1 3.33 - - - - 
24 3 10.00 - - - - - - 
30 1 3.33 - - - - - - 
TOTAL 30 100 30 100 30 100 30 100 
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Sensory block level 
 GROUP-A GROUP-B GROUP-C GROUP-D 
N % N % N % N % 
T6 7 23.33 5 16.66 6 20.0 7 23.3 
T8 18 60.00 20 66.67 19 63.33 18 60.00 
T10 5 16.67 5 16.67 5 16.67 5 16.67 
TOTAL 30 100 30 100 30 100 30 100 
 
 The sensory blockade level was comparable between the four 
groups and it is statistically insignificant. 
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 In group A 24 patients, in group B 10 patients, in group C 1 patient 
and in group D none had hypotension respectively. 
 In group D 14 patients had hypertension which needed tapering 
down of dopamine infusion to 5mcg/kg/min. 
 None had bradycardia or tachycardia, but group A patients had a 
statistically significant lower heart rate after T30, when compared 
to group B, C and D. 
 
 
 
Group Hypertension Hypotension Bradycardia 
Hr<50/mt 
Desaturation 
Spo2<95 
Tachycardia  
Hr >100/mt 
A 0/30 24/30 0 0 0 
B 0/30 10/30 0 0 0 
C 0/30 1/30 0 0 0 
D 14/30 0/30 0 0 0 
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 There was a significant difference in urine output noted between 
the control group A and groups which received dopamine infusion. 
 The average volume of urine in control group is 73.9 ml at the end 
of 60 minutes,  but it was around 10 times more in group B , C 
and D. 
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DISCUSSION 
With very few exceptions, the effects of spinal anesthesia on the 
cardiovascular system are almost entirely because of block of the 
preganglionic sympathetic fibers by the local anesthetic injected in the 
subarachnoid space . 
Physiologic trespass is directly related to the intrathecal level of 
sympathetic denervation. The degree to which the spinal anesthetic 
alters the normal hemodynamic status, however, varies considerably. 
Differences may be due to many factors, including the general 
state of health, age, intravascular fluid status, and concurrent 
medications. In general, more extensive sympathetic block produces 
more profound hemodynamic changes. The effects of sympathetic 
denervation are extensive, both on the arterial and venous vessels. 
Hence sympathomimetics are the mainstay in the management of 
central neuraxial blockade induced hypotension. 
In our study dopamine was used premptively as vasopressor in 
three different doses 3,5,7 mcg per kg per minute, to compare the intra 
operative hemodynamics of various doses of dopamine infusion. 
Dopamine at a dose of 5mcg/kg/min increases the BP without 
obviously affecting the HR. Thus, it can be used to control 
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hemodynamics during spinal anesthesia, without increasing 
myocardial consumption.  
We investigated the effects of continuous intravenous infusion of 
dopamine at 3, 5, and 7 µg/kg/min on the hemodynamic parameters of 
patients undergoing surgeries under spinal anesthesia. Systolic BP and 
MAP  were higher in Groups C and D compared to Group A 
suggesting that continuous intravenous infusion of dopamine at 5 or 7 
µg/kg/min is effective in maintaining hemodynamic stability during 
surgery. 
HR was not increased in Group B,C or D when compared with 
Group A, suggesting that dopamine does not cause tachycardia even at 
a dose of 7mcg/kg/mt. 
However, the hypertension incidence was higher in Group D than 
in any other group. Therefore, even though it maintains the 
hemodynamic stability, continuous intravenous infusion of 7 
µg/kg/min dopamine may not be safe for patients.  
Overall, our findings indicate that continuous intravenous infusion 
of 5µg/ kg/min dopamine may be safe and effective in controlling 
hemodynamic stability for patients undergoing surgeries under spinal 
anaesthesia.  
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In Cabalum et al32 study Infusion of dopamine during the spinal 
hypotension corrected the disturbed circulatory parameters. Dopamine 
represented a useful agent in the management of spinal hypotension. 
In our study also dopamine at a dose of 5mcg/kg/minute was able 
to maintain stable intraoperative systolic and mean arterial pressure 
when compared to ephedrine iv boluses . 
The effects of dopamine on hemodynamic parameters were 
examined at several time points before and during surgery. In the 
control group, systolic BP,MAP was lower at T2–T100compared to 
T1, suggesting that spinal anesthesia induced hypotension in these 
patients were not well managed by intermittent ephedrine intravenous 
boluses.  
Frazer RS Edwards GM. et al43 ,Kang YG, Abouleish E, 
Caritis S. et al44,Gajraj NM, Victory RA, Pace NA, Van Elstraete 
AC, Wallace DH.et al45 ,Hemmingsen C, Poulsen JA, Risbo A. Et 
al46.All the above four studies mentioned that prophylactic ephedrine 
administration prevented hypotension in patients underwent central 
neuraxial blockade but in our study control group received only iv 
intermittent boluses and they had a wide variation in systolic and 
mean arterial pressures when compared to dopamine infusion group C. 
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In Group B, systolic BP,MAP were low and not different from 
those in Group A, suggesting that continuous intravenous infusion of 
3µg/kg/min dopamine did not effectively control hemodynamic 
stability.  
Butterworth et al34 studied the effectiveness of dopamine as 
possible alternative to ephedrine for the pharmacologic correction of 
the non cardiac circulatory sequelae of spinal anesthesia was 
demonstrated and Lundberg et al35 found that myocardial 
contractility and arterial pressure were restored to pre-thoracic 
epidural analgesia values by dopamine at 5–10 μg · kg-1 · min-1. 
In our study also we found that dopamine infusion at a dose of 
5mcg/kg/min can be used as a safe alternative to ephedrine iv boluses 
for spinal anaesthesia induced hypotension and dopamine infusion had 
a better cardiovascular stability when compared to ephedrine group 
and there was no tachycardia reported even at the dose of 
7mcg/kg/min. 
 
Coe AJ, Revanäs B. Et al48 did a study using crystalloid 
preloading to assess usefulness in spinal anaesthesia in the elderly.And 
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concluded that Crystalloid preloading had no effect on the incidence 
of hypotension after spinal anaesthesia in fit, elderly patients. 
In our study even after preloading with crystalloids@15ml/kg, 
group A patients had hypotension necessitating ephedrine intravenous 
boluses. But in group B, 10 patients required ephedrine bolus, in group 
C only one patient needed ephedrine bolus and in group D patients did 
not require ephedrine bolus. 
Moreover patients in group B,C&D had an average urine output of  
>700 ml at the end of 60 minutes,indicating that patients received 
dopamine had a better hemodynamics compared to intermittent 
ephedrine boluses. 
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SUMMARY 
In this study 
 We observed that dopamine continuous infusion @ 
5mcg/kg/min prevented spinal anaesthesia induced hypotension 
effectively without causing significant tachycardia. 
 We observed that dopamine infusion @ 3mcg/kg/min was not 
able to maintain stable hemodynamics in patients undergoing surgeries 
under spinal anaesthesia. 
 We observed that dopamine infusion @ 7mcg/kg/min was 
even though able to prevent spinal anaesthesia induced hypotension,it 
produced hypertension in significant number of patients. 
 We observed that intermittent intravenous ephedrine boluses 
failed to prevent the spinal anaesthesia induced hypotension. 
 We also observed that patients who received dopamine 
infusion had a higher urine output in all 3 doses when compared to 
control group. 
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CONCLUSION 
With this study we conclude that preemptive dopamine continuous 
intravenous infusion at a dose of 5 mcg/kg/min effectively prevented 
spinal anaesthesia induced hypotension when compared to intravenous 
intermittent ephedrine boluses without any significant adverse 
effects.Hence with this study we recommend that dopamine @ 
5mcg/kg/min infusion can be used as a safe alternative for intermittent 
ephedrine iv boluses. 
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PROFORMA 
Name:  
Age:  
Sex: 
IPno:                                                                          
Ward/ SU 
Group: 
Date of admission:                                                 
Date of surgery: 
ASA Physical Status: 
Co- Morbidity: 
Patient on any drugs: 
Preoperative  examination: 
     Blood pressure: 
     Pulse rate : 
     Room air SpO2: 
     Cardiovascular system: 
     Respiratory system: 
     Central nervous system:  
Diagnosis:                                                                                                
Surgery being performed:                                                                   
Investigations:   
Premedication:  
  
 
                                                                           
Time of injection of study drug: 
Group (Tick any one) 
  Group-A: patients who do not receive dopamine infusion 
  Group-B: patients who receive dopamine infusion@3mcg/kg/mt 
  Group-C:patients who receive dopamine infusion@5mcg/kg/mt 
  Group-D:Patients who receive dopamineinfusion@7mcg/kg/mt  
Duration of surgery :   
Position during surgery:            
OBSERVATIONS: 
INTRAOPERATIVE PARAMETERS: 
TIME  SBP    
DBP 
MAP HR SPO2 URINE 
OUTPUT 
1 Min. after SAB¶       
5 Min. after SAB. 
¶ 
      
10Min. after SAB. 
¶ 
      
15 Min. after 
SAB¶. 
      
20 Min. after 
SAB. ¶ 
      
25 Min. after 
SAB. ¶ 
      
  
 
30 Min. after 
SAB. ¶ 
      
40 Min. after 
SAB¶ 
      
50 Min. after 
SAB. ¶ 
      
60 Min. after 
SAB. ¶ 
      
70 Min. after 
SAB. ¶ 
      
80 Min. after 
SAB. ¶ 
      
90 min after SAB       
100 min afer SAB       
110 min after SAB       
120 min after SAB       
 
 
 
 
 
 
 
 
 
  
 
PATIENT CONSENT FORM 
Study detail :    A PROSPECTIVE RANDOMISED CONTROL STUDY OF EFFECTS 
OF VARIOUS DOSES OF DOPAMINE CONTINUOUS INTRAVENOUS INFUSION ON 
THE INTRAOPERATIVE HEMODYNAMICS  IN PATIENTS UNDERGOING ELECTIVE 
SURGERIES UNDER SPINAL ANAESTHESIA 
Study Centre :   GOVT. KILPAUK  MEDICAL  COLLEGE HOSPITAL  & 
GOVT.   ROYAPETTAH HOSPITAL, CHENNAI. 
Patients Name  : 
Patients Age  : 
Identification Number        : 
   Patient may check (     ) these boxes 
I  confirm that I have understood the purpose of procedure for the above study. I have the 
opportunity to ask question and all my questions and doubts have been answered to my complete 
satisfaction. 
I understand that my participation in the study is voluntary and that I am free to withdraw at any 
time without giving reason, without my legal rights being affected. 
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, the ethical 
committee and the regulatory authorities will not need my permission to look at my health records, 
both in respect of current study and any further research that may be conducted in relation to it, 
even if I withdraw from the study I agree to this access. However, I understand that my identity 
will not be revealed in any information released to third parties or published, unless as required 
under the law. I agree not to restrict the use of any data or results that arise from this study. 
I agree to take part in the above study and to comply with the instructions given during the study 
and faithfully cooperate with the study team and to immediately inform the study staff if I suffer 
from any deterioration in my health or well-being or any unexpected or unusual symptoms. 
I hereby consent to participate in this study. 
I hereby give permission to undergo complete clinical examination and diagnostic tests including 
hematological, biochemical, radiological tests. 
                                                                                                           
Signature/thumb impression:  
Patients Name and Address:                                place   date 
Signature of investigator :    
 
Study investigator’s Name :                             place   date      
  
 
  
 
 
 
 
 
 
 
 
 
 
 
name 
age sex 
asa 
status 
height weight Diagnosis procedure 
preop 
sbp 
preop 
dbp 
preop 
map 
preop 
hr 
sbp1 dbp1 map1 hr1 
anzad basha 33 m ps1 165 56 RIH hernioplasty 134 88 103 68 122 85 97 68 
kannan 38 m ps1 170 70 B/LIH hernioplasty 140 80 101 86 133 86 98 76 
leon josephine 49 m ps1 158 52 LIH hernioplasty 120 78 96 90 122 75 95 94 
gangammal 55 f ps2 155 56 IN.H hernioplasty 157 105 122 106 109 71 84 118 
aarumugam 64 m ps2 165 58 RIH hernioplasty 124 90 101 78 110 70 88 76 
ramachandran 65 m ps2 162 50 LIH hernioplasty 155 82 106 68 130 74 93 76 
loganathan 40 m ps1 165 70 RIH hernioplasty 122 80 90 80 119 78 88 82 
chellammal 60 f ps2 152 56 RIH hernioplasty 150 80 104 95 140 86 98 90 
premkumar 25 m ps1 164 62 RIH hernioplasty 107 65 79 93 113 79 90 88 
suresh 40 m ps1 168 58 RIH hernioplasty 121 82 95 88 119 82 92 106 
kannaiah 43 m ps2 157 53 LIH hernioplasty 150 90 108 88 120 89 99 86 
raj 45 m ps1 165 66 LIH hernioplasty 147 94 109 80 133 76 94 76 
antony raj 38 m ps1 164 58 RIH hernioplasty 120 68 96 64 119 68 93 63 
velmurugan 40 m ps1 170 70 LIH hernioplasty 156 104 120 110 148 95 104 103 
parasuraman 34 m ps1 158 55 LIH hernioplasty 150 70 120 90 149 91 108 88 
engel shaw 27 m ps1 170 70 RIH hernioplasty 133 88 101 68 122 87 92 61 
pencillaiah 55 m ps2 156 45 LIH hernioplasty 133 88 101 84 101 76 86 86 
akbar  64 m ps1 162 55 RIH hernioplasty 142 86 104 88 136 72 98 86 
veerasamy 65 m ps2 168 58 LIH hernioplasty 146 84 98 64 117 60 78 60 
vijaya 43 f ps2 155 60 UH hernioplasty 142 85 104 95 109 65 80 92 
ayyappan 62 m ps2 158 54 LIH hernioplasty 134 86 101 64 110 72 78 61 
sanny 60 m ps2 170 60 IN.H hernioplasty 150 86 106 102 147 89 107 108 
bakthavatchalam 64 m ps2 168 65 RIH hernioplasty 150 88 107 94 140 90 100 88 
rajkumar 48 m ps2 165 58 RIH hernioplasty 128 90 101 80 124 89 100 78 
chandran 63 p ps2 162 50 LIH hernioplasty 154 84 104 70 155 82 106 68 
kumar 25 m ps1 168 62 RIH hernioplasty 114 80 92 94 107 65 79 93 
barathan 64 m ps1 166 58 RIH hernioplasty 142 86 104 88 136 72 98 86 
paramesh 34 m ps1 158 55 LIH hernioplasty 150 70 120 90 149 91 108 88 
rajasekar 45 m ps1 165 66 LIH hernioplasty 149 96 109 82 147 94 109 80 
surendar 40 m ps1 168 68 RIH hernioplasty 128 86 98 84 121 82 95 88 
Master chart group A Master chart group A 
  
 
sbp2 dbp2 map2 hr2 sbp3 dbp3 map3 hr3 sbp4 dbp4 map4 hr4 sbp5 dbp5 map5 hr5 
121 88 97 71 96 69 78 60 101 70 80 59 101 70 80 59 
130 84 97 77 128 85 96 78 132 84 97 74 133 87 100 72 
116 74 82 93 112 74 81 91 112 76 81 92 111 72 86 91 
92 59 70 110 85 56 66 99 90 60 70 105 89 61 70 106 
106 73 84 76 104 75 85 66 105 75 85 77 93 75 81 52 
69 41 50 51 85 51 62 53 85 51 62 56 89 52 64 57 
118 77 87 76 112 73 81 74 112 73 81 76 113 72 82 69 
135 85 92 88 128 72 88 86 108 68 76 83 99 61 70 80 
98 65 76 89 98 65 76 86 99 66 77 69 98 64 75 72 
116 72 90 102 114 74 92 98 109 68 76 82 109 67 76 72 
90 61 70 78 84 57 68 80 108 72 76 85 103 71 78 78 
99 63 73 69 106 65 78 69 98 60 74 66 115 70 85 68 
127 68 97 61 117 62 88 62 110 59 72 60 112 60 81 63 
131 88 98 102 127 84 90 98 133 98 104 98 130 88 100 92 
150 88 106 100 150 85 104 100 150 90 108 104 141 85 102 88 
120 80 90 59 118 78 89 61 119 80 90 64 122 83 92 62 
88 57 67 89 103 67 78 88 101 66 77 76 90 60 68 75 
124 74 96 84 110 72 92 84 104 68 84 80 99 63 74 78 
89 51 63 61 97 56 67 63 97 56 67 57 100 52 64 58 
85 49 61 70 103 69 80 96 89 59 69 90 105 72 83 98 
98 65 75 62 104 72 79 61 115 78 87 63 119 80 90 64 
140 87 101 107 147 84 103 105 149 92 110 109 129 83 95 108 
117 77 86 69 111 67 90 87 103 63 76 81 110 68 85 82 
110 72 89 76 106 73 84 76 104 75 85 66 105 75 85 77 
130 74 93 76 69 41 50 51 85 51 62 53 85 51 62 56 
113 79 90 88 98 65 76 89 98 65 76 86 99 66 77 69 
124 74 96 84 110 72 92 84 104 68 84 80 99 63 74 78 
150 88 106 100 150 85 104 100 150 90 108 104 141 85 102 88 
133 76 94 76 99 63 73 69 106 65 78 69 98 60 74 66 
119 82 92 106 116 72 90 102 114 74 92 98 109 68 76 82 
sbp10 dbp10 map10 hr10 sbp15 dbp15 map15 hr15 sbp20 dbp20 map20 hr20 sbp25 dbp25 map25 hr25 
  
 
101 71 82 59 101 72 82 59 101 72 82 58 101 72 82 58 
129 84 95 78 128 84 95 72 129 84 95 69 132 84 97 64 
115 69 86 85 107 64 74 81 104 65 72 77 99 63 70 79 
87 61 70 102 109 69 82 104 102 68 79 99 100 60 73 81 
114 78 90 56 119 86 97 82 112 82 92 78 102 76 85 77 
87 52 64 58 105 59 74 57 104 58 73 58 101 57 71 56 
111 73 81 69 111 72 81 71 113 72 82 70 108 65 78 73 
89 58 68 80 102 72 78 78 110 63 80 78 96 58 66 62 
97 63 74 67 92 57 69 60 92 56 68 58 92 55 67 58 
95 61 76 72 94 64 72 67 96 59 67 67 98 67 90 66 
96 65 74 78 99 71 75 74 110 79 84 74 104 74 82 72 
106 62 78 69 95 59 68 65 103 62 72 66 96 59 73 62 
116 50 71 58 109 54 81 58 113 56 72 57 104 54 75 58 
124 84 95 88 121 80 91 78 121 81 91 76 129 85 97 84 
138 80 96 76 136 79 94 77 137 85 96 77 134 81 92 77 
130 83 96 65 133 90 102 61 133 89 102 65 130 87 100 63 
97 64 74 75 86 57 69 72 98 76 82 74 84 56 62 70 
119 66 81 80 103 53 75 82 112 65 78 68 108 66 78 66 
98 52 66 58 99 52 64 58 102 55 68 54 103 56 71 56 
104 70 81 97 102 67 79 90 100 66 77 91 100 66 77 88 
127 86 96 62 130 84 96 61 119 81 89 59 127 84 95 60 
119 80 89 108 121 81 91 102 107 68 78 103 118 79 88 95 
132 84 90 76 120 76 86 60 119 75 86 58 119 73 84 57 
93 75 81 52 114 78 90 56 119 86 97 82 112 82 92 78 
89 52 64 57 87 52 64 58 105 59 74 57 104 58 73 58 
98 64 75 72 97 63 74 67 92 57 69 60 92 56 68 58 
119 66 81 80 103 53 75 82 112 65 78 68 108 66 78 66 
138 80 96 76 136 79 94 77 137 85 96 77 134 81 92 77 
115 70 85 68 106 62 78 69 95 59 68 65 103 62 72 66 
109 67 76 72 95 61 76 72 94 64 72 67 96 59 67 67 
 
  
 
 
 
 
 
 
 
 
 
 
sbp30 dbp30 map30 hr30 sbp40 dbp40 map40 hr40 sbp50 dbp50 map50 hr50 sb60 dbp60 map60 hr60 
u/o 
60 
100 72 81 59 99 72 81 58 106 77 87 70 98 74 82 58 75 
140 89 104 70 129 85 97 63 121 84 79 62 130 84 96 62 100 
97 56 67 78 100 56 67 71 99 59 68 72 105 62 79 71 50 
99 60 73 90 92 57 69 81 97 57 70 85 94 59 71 92 50 
98 73 81 77 93 68 76 62 100 76 84 76 95 73 80 77 50 
100 57 71 55 109 57 76 60 110 68 80 66 109 68 78 69 100 
115 75 84 70 130 81 93 71 123 82 92 83 130 83 96 82 50 
107 61 74 64 108 59 76 67 105 55 70 64 108 60 78 70 75 
91 55 67 55 91 53 66 55 94 56 69 58 94 57 69 59 0 
97 60 75 65 97 62 75 65 102 63 77 60 106 69 86 60 100 
118 80 89 70 111 76 82 68 115 80 90 68 117 80 89 64 50 
105 63 77 62 99 60 71 62 105 63 73 63 113 64 87 58 75 
106 60 76 56 107 60 80 55 105 49 74 56 102 51 76 53 100 
129 85 97 85 131 85 99 71 147 88 104 69 147 92 108 71 100 
135 83 94 73 135 81 99 70 132 80 98 71 132 90 101 70 50 
133 88 101 67 129 87 99 60 140 93 107 61 132 89 101 61 50 
101 71 78 70 96 65 74 69 99 67 81 68 96 66 75 63 50 
110 68 76 69 106 64 74 70 110 68 78 68 114 69 78 72 50 
109 58 73 55 111 60 76 54 112 62 78 55 112 62 78 53 100 
99 65 76 84 97 62 74 83 106 72 83 89 106 70 82 83 75 
122 81 90 58 127 80 93 61 120 82 91 61 128 85 96 57 75 
106 73 81 82 96 64 74 97 128 79 92 92 124 81 92 92 100 
118 72 83 60 119 74 85 59 120 71 84 58 123 74 86 64 75 
102 76 85 77 98 73 81 77 93 68 76 62 100 76 84 76 100 
101 57 71 56 100 57 71 55 109 57 76 60 110 68 80 66 100 
92 55 67 58 91 55 67 55 91 53 66 55 94 56 69 58 0 
110 68 76 69 106 64 74 70 110 68 78 68 114 69 78 72 50 
135 83 94 73 135 81 99 70 132 80 98 71 132 90 101 70 50 
96 59 73 62 105 63 77 62 99 60 71 62 105 63 73 63 75 
98 67 90 66 97 60 75 65 97 62 75 65 102 63 77 60 100 
  
 
 
 
 
 
 
 
 
 
 
 
sbp70 dbp70 map70 hr70 sbp80 dbp80 map80 hr80 sbp90 dbp90 map90 hr90 sbp100 dbp100 map100 hr100 
111 77 88 60 109 74 86 60 106 72 83 59     
123 83 94 66 129 89 100 60         
100 56 69 69 99 60 76 74 100 70 82 74     
95 60 72 78 100 64 76 85 110 67 81 88     
96 73 81 80 97 74 82 77 97 75 82 71 100 78 85 80 
                
129 83 95 78             
121 66 82 67 109 60 81 63 113 62 84 64 121 65 88 72 
94 57 69 58 101 60 74 62 100 60 73 58 112 78 82 62 
116 68 86 60 115 74 86 60 112 73 94 60 122 74 100 64 
119 83 90 64 120 85 92 66         
112 65 91 62 109 72 90 60 119 72 102 63 129 74 90 64 
107 51 73 54 106 53 69 58 102 53 68 52 104 48 66 54 
144 92 107 78 143 95 109 78 142 94 108 78 144 96 111 80 
                
131 91 102 60 131 87 100 56 140 91 105 56 134 90 103 58 
93 65 73 68 98 66 76 64 102 70 78 60 106 72 80 62 
118 72 80 68 122 78 82 69         
111 61 77 57 120 64 79 52 117 62 78 53 119 64 78 56 
106 70 82 84 107 70 82 79 105 70 82 82 107 72 84 84 
134 86 101 61 124 84 96 71         
114 78 86 94 108 68 78 95 113 71 82 77 111 74 83 89 
119 72 83 59 133 78 92 62 121 77 88 62 127 75 88 66 
95 73 80 77 96 73 81 80 97 74 82 77 97 75 82 71 
109 68 78 69             
94 57 69 59 94 57 69 58 101 60 74 62 100 60 73 58 
118 72 80 68 122 78 82 69         
                
113 64 87 58 112 65 91 62 109 72 90 60 119 72 102 63 
106 69 86 60 116 68 86 60 115 74 86 60 112 73 94 60 
  
 
 
 
 
 
 
 
 
 
 
 
Sbp 
110 
Dbp 
110 
Map 
110 
Hr 
110 
Sbp 
120 
Dbp 
120 
Map 
120 
hr120 
u/o 
120 
ephedrine 
ephedrine 
dose(mg) 
atropine SPO2<95 
Sens.bloc 
level 
         Y 18 N N T8 
         N 0 N N T8 
         Y 18 N N T8 
         Y 24 N N T6 
102 78 86 77     150 Y 6 N N T8 
         Y 18 N N T8 
         N 0 N N T10 
         Y 18 N N T6 
         Y 12 N N T6 
         Y 12 N N T8 
         Y 18 N N T8 
         Y 24 N N T6 
107 49 72 56     150 Y 18 N N T8 
         N 0 N N T10 
         N 0 N N T10 
         N 0 N N T10 
         Y 30 N N T8 
         Y 18 N N T8 
117 62 78 55 115 63 79 51 200 Y 18 N N T8 
108 72 84 78 109 72 84 78 150 Y 18 N N T6 
         Y 6 N N T8 
117 77 86 76 122 80 90 81  Y 12 N N T8 
122 78 88 61      Y 12 N N T8 
100 78 85 80 102 78 86 77 150 Y 6 N N T8 
         Y 18 N N T8 
112 78 82 62      Y 12 N N T6 
         Y 18 N N T8 
         N 0 N N T10 
129 74 90 64      Y 24 N N T6 
  
 
 
 
 
 
 
 
 
 
 
 
Name age sex 
asa 
status 
ht wt Diag procedure preop sbp 
preop 
dbp 
preop 
map 
preop hr sbp1 dbp1 map1 
thangamani 47 m ps1 158 54 LIH hernioplasty 128 76 98 78 119 76 91 
Chinnaiah 62 m ps2 160 58 LIH hernioplasty 142 81 98 88 124 77 89 
usman basha 25 m ps1 166 60 RIH hernioplasty 134 80 98 98 129 82 98 
Rajagopal 52 m ps2 164 50 RIH hernioplasty 119 81 90 102 119 77 88 
Rajesh 40 m ps1 155 57 LIH hernioplasty 134 78 100 82 128 76 98 
Kiran 60 m ps2 168 62 RIH hernioplasty 135 84 99 96 134 80 98 
Jagannath 25 m ps1 165 54 RIH hernioplasty 124 80 90 100 118 78 89 
Rekha 40 f ps2 153 55 UH hernioplasty 130 81 101 80 118 80 90 
umesh kumar 43 m ps1 167 66 RIH hernioplasty 136 80 100 98 130 84 98 
Soorya 45 m ps2 160 59 RIH hernioplasty 120 82 91 88 108 78 88 
Anzad 38 m ps1 152 64 LIH hernioplasty 128 76 98 78 119 76 91 
Ibrahim 40 m ps2 163 70 RIH hernioplasty 134 80 98 98 129 82 98 
Mohan 34 m ps1 168 63 RIH hernioplasty 121 80 90 102 119 77 88 
Shalab 27 m ps1 156 58 LIH hernioplasty 128 76 98 78 119 76 91 
parameswari 55 f ps2 159 65 IN.H hernioplasty 134 80 98 98 129 82 98 
Saravanan 64 m ps2 161 63 RIH hernioplasty 119 81 90 102 119 77 88 
Ramesh 65 m ps1 166 54 LIH hernioplasty 128 76 98 78 119 76 91 
Santhanam 43 m ps1 162 66 RIH hernioplasty 134 80 98 98 129 82 98 
Krishnan 62 m ps2 165 56 RIH hernioplasty 119 81 90 102 119 77 88 
barath kumar 60 m ps1 157 55 LIH hernioplasty 128 76 98 78 119 76 91 
Madhusudanan 64 m ps2 166 61 RIH hernioplasty 134 80 98 98 129 82 98 
Latha 48 f ps1 170 53 UH hernioplasty 119 81 90 102 119 77 88 
nambirajan 63 m ps1 157 48 LIH hernioplasty 128 76 98 78 119 76 91 
ilaya murugan 25 m ps1 169 60 RIH hernioplasty 134 80 98 98 129 82 98 
Nagendran 64 m ps2 165 54 RIH hernioplasty 119 81 90 102 119 77 88 
Rajendran 34 m ps1 150 42 LIH hernioplasty 128 76 98 78 119 76 91 
Sivakumar 45 m ps1 161 60 RIH hernioplasty 142 83 118 88 132 71 92 
jayaprakash 40 m ps1 165 66 RIH hernioplasty 119 81 90 102 119 77 88 
Magesh 45 m ps1 155 55 LIH hernioplasty 128 76 98 78 119 76 91 
muthukumar 48 m ps2 164 58 RIH hernioplasty 123 83 93 97 119 81 90 
Master chart group B 
  
 
 
 
 
 
 
 
 
 
 
 
sbp2 dbp2 map2 hr2 sbp3 dbp3 map3 hr3 sbp4 dbp4 map4 hr4 sbp5 dbp5 map5 hr5 
110 72 81 84 109 65 79 81 107 67 79 83 97 62 73 81 
103 63 76 86 91 58 67 90 92 59 68 85 86 52 63 71 
128 82 97 84 127 82 97 83 126 82 97 99 125 84 98 84 
104 64 76 98 99 60 71 96 102 56 69 98 93 53 63 100 
119 76 91 78 110 72 81 84 109 65 79 81 107 67 79 83 
129 82 98 89 128 82 97 84 127 82 97 83 126 82 97 99 
114 64 79 99 98 61 72 98 112 58 70 96 92 52 64 101 
109 70 80 82 108 63 78 80 106 66 78 81 99 64 72 80 
126 80 96 82 124 80 95 81 122 82 97 99 125 84 98 84 
104 72 84 86 102 70 80 84 103 58 70 82 92 52 65 85 
110 72 81 84 109 65 79 81 107 67 79 83 97 62 73 81 
128 82 97 84 127 82 97 83 126 82 97 99 125 84 98 84 
104 64 76 98 99 60 71 96 102 56 69 98 93 53 63 100 
110 72 81 84 109 65 79 81 107 67 79 83 97 62 73 81 
128 82 97 84 127 82 97 83 126 82 97 99 125 84 98 84 
104 64 76 98 99 60 71 96 102 56 69 98 93 53 63 100 
110 72 81 84 109 65 79 81 107 67 79 83 97 62 73 81 
128 82 97 84 127 82 97 83 126 82 97 99 125 84 98 84 
104 64 76 98 99 60 71 96 102 56 69 98 93 53 63 100 
110 72 81 84 109 65 79 81 107 67 79 83 97 62 73 81 
128 82 97 84 127 82 97 83 126 82 97 99 125 84 98 84 
104 64 76 98 99 60 71 96 102 56 69 98 93 53 63 100 
110 72 81 84 109 65 79 81 107 67 79 83 97 62 73 81 
128 82 97 84 127 82 97 83 126 82 97 99 125 84 98 84 
104 64 76 98 99 60 71 96 102 56 69 98 93 53 63 100 
110 72 81 84 109 65 79 81 107 67 79 83 97 62 73 81 
137 64 89 91 137 64 95 89 133 59 94 91 132 55 86 83 
104 64 76 98 99 60 71 96 102 56 69 98 93 53 63 100 
110 72 81 84 109 65 79 81 107 67 79 83 97 62 73 81 
118 80 89 91 119 78 88 90 117 76 85 84 120 77 87 82 
  
 
 
 
 
 
 
 
 
 
 
 
sbp10 dbp10 map10 hr10 sbp15 dbp15 map15 hr15 sbp20 dbp20 map20 hr20 sbp25 dbp25 map25 hr25 
97 59 71 77 100 63 74 77 98 62 73 69 99 61 73 68 
109 67 79 78 126 67 82 78 144 75 100 75 146 80 100 78 
125 83 97 86 124 92 108 69 124 84 97 62 122 75 91 60 
88 57 64 102 102 63 75 96 105 62 76 95 103 65 77 94 
97 62 73 81 97 59 71 77 100 63 74 77 98 62 73 69 
125 84 98 84 125 83 97 86 124 92 108 69 124 84 97 62 
89 58 66 106 101 63 75 96 105 62 76 95 103 65 77 94 
96 58 70 78 101 64 74 76 99 61 74 68 100 62 74 70 
125 83 97 86 124 92 108 69 124 84 97 62 122 75 91 60 
86 56 62 78 100 60 74 78 106 68 80 74 110 68 81 76 
97 59 71 77 100 63 74 77 98 62 73 69 99 61 73 68 
125 83 97 86 124 92 108 69 124 84 97 62 122 75 91 60 
88 57 64 102 102 63 75 96 105 62 76 95 103 65 77 94 
97 59 71 77 100 63 74 77 98 62 73 69 99 61 73 68 
125 83 97 86 124 92 108 69 124 84 97 62 122 75 91 60 
88 57 64 102 102 63 75 96 105 62 76 95 103 65 77 94 
97 59 71 77 100 63 74 77 98 62 73 69 99 61 73 68 
125 83 97 86 124 92 108 69 124 84 97 62 122 75 91 60 
88 57 64 102 102 63 75 96 105 62 76 95 103 65 77 94 
97 59 71 77 100 63 74 77 98 62 73 69 99 61 73 68 
125 83 97 86 124 92 108 69 124 84 97 62 122 75 91 60 
88 57 64 102 102 63 75 96 105 62 76 95 103 65 77 94 
97 59 71 77 100 63 74 77 98 62 73 69 99 61 73 68 
125 83 97 86 124 92 108 69 124 84 97 62 122 75 91 60 
88 57 64 102 102 63 75 96 105 62 76 95 103 65 77 94 
97 59 71 77 100 63 74 77 98 62 73 69 99 61 73 68 
137 64 95 74 130 67 92 72 132 65 86 71 131 66 95 74 
88 57 64 102 102 63 75 96 105 62 76 95 103 65 77 94 
97 59 71 77 100 63 74 77 98 62 73 69 99 61 73 68 
111 66 79 83 109 67 78 81 111 73 82 70 112 72 81 81 
  
 
sbp30 dbp30 map30 hr30 sbp40 dbp40 map40 hr40 sbp50 dbp50 map50 hr50 sb60 dbp60 map60 hr60 u/o 60 
101 62 74 67 101 64 75 68 103 64 76 67 104 69 78 69 1000 
134 73 90 81 122 72 85 77 124 71 86 77 129 73 88 70 700 
126 79 95 61 125 80 95 65 120 81 94 63 122 81 95 63 500 
109 63 78 95 115 67 81 100 120 72 84 93 113 65 78 96 450 
99 61 73 68 101 62 74 67 101 64 75 68 103 64 76 67 650 
122 75 91 60 126 79 95 61 125 80 95 65 120 81 94 63 550 
109 63 78 95 115 67 81 100 120 72 84 93 113 65 78 96 450 
101 64 75 69 102 65 76 69 102 65 75 69 105 70 79 74 800 
126 79 95 61 125 80 95 65 120 81 94 63 122 81 95 63 500 
122 75 91 60 126 79 95 61 125 80 95 65 120 81 94 63 600 
101 62 74 67 101 64 75 68 103 64 76 67 104 69 78 69 900 
126 79 95 61 125 80 95 65 120 81 94 63 122 81 95 63 500 
109 63 78 95 115 67 81 100 120 72 84 93 113 65 78 96 450 
101 62 74 67 101 64 75 68 103 64 76 67 104 69 78 69 400 
126 79 95 61 125 80 95 65 120 81 94 63 122 81 95 63 900 
109 63 78 95 115 67 81 100 120 72 84 93 113 65 78 96 450 
101 62 74 67 101 64 75 68 103 64 76 67 104 69 78 69 700 
126 79 95 61 125 80 95 65 120 81 94 63 122 81 95 63 500 
109 63 78 95 115 67 81 100 120 72 84 93 113 65 78 96 450 
101 62 74 67 101 64 75 68 103 64 76 67 104 69 78 69 800 
126 79 95 61 125 80 95 65 120 81 94 63 122 81 95 63 500 
109 63 78 95 115 67 81 100 120 72 84 93 113 65 78 96 750 
101 62 74 67 101 64 75 68 103 64 76 67 104 69 78 69 650 
126 79 95 61 125 80 95 65 120 81 94 63 122 81 95 63 500 
109 63 78 95 115 67 81 100 120 72 84 93 113 65 78 96 450 
101 62 74 67 101 64 75 68 103 64 76 67 104 69 78 69 700 
133 63 83 85 140 60 91 82 143 67 93 76 140 56 94 72 500 
109 63 78 95 115 67 81 100 120 72 84 93 113 65 78 96 550 
101 62 74 67 101 64 75 68 103 64 76 67 104 69 78 69 800 
113 76 84 81 121 80 90 86 118 73 84 84 120 73 85 73 400 
 
  
 
sbp70 dbp70 map70 hr70 sbp80 dbp80 map80 hr80 sbp90 dbp90 map90 hr90 sbp100 dbp100 map100 hr100 
104 63 76 64 111 67 78 70 109 71 81 70     
133 75 91 73 133 74 90 77 133 80 95 75     
130 87 101 74 130 81 97 62 128 81 97 66 124 88 100 58 
119 60 78 96 118 71 83 97 120 71 83 92 121 72 84 91 
104 69 78 69 104 63 76 64 111 67 78 70 109 71 81 70 
122 81 95 63 130 87 101 74 130 81 97 62 128 81 97 66 
119 60 78 96 118 71 83 97 120 71 83 92 121 72 84 91 
106 64 78 65 114 68 79 68 110 70 80 72 111 72 82 74 
130 87 101 74 130 81 97 62 128 81 97 66 124 88 100 58 
119 60 78 96 118 71 83 97 120 71 83 92     
104 63 76 64 111 67 78 70 109 71 81 70     
130 87 101 74 130 81 97 62 128 81 97 66 124 88 100 58 
119 60 78 96 118 71 83 97 120 71 83 92 121 72 84 91 
104 63 76 64 111 67 78 70 109 71 81 70     
130 87 101 74 130 81 97 62 128 81 97 66 124 88 100 58 
119 60 78 96 118 71 83 97 120 71 83 92 121 72 84 91 
104 63 76 64 111 67 78 70 109 71 81 70     
130 87 101 74 130 81 97 62 128 81 97 66 124 88 100 58 
119 60 78 96 118 71 83 97 120 71 83 92 121 72 84 91 
104 63 76 64 111 67 78 70 109 71 81 70     
130 87 101 74 130 81 97 62 128 81 97 66 124 88 100 58 
119 60 78 96 118 71 83 97 120 71 83 92 121 72 84 91 
104 63 76 64 111 67 78 70 109 71 81 70     
130 87 101 74 130 81 97 62 128 81 97 66 124 88 100 58 
119 60 78 96 118 71 83 97 120 71 83 92 121 72 84 91 
104 63 76 64 111 67 78 70 109 71 81 70     
148 56 96 71 139 67 94 77 133 70 94 78     
119 60 78 96 118 71 83 97 120 71 83 92 121 72 84 91 
104 63 76 64 111 67 78 70 109 71 81 70     
111 73 82 75 112 75 83 79 119 76 89 75 122 81 91 77 
 
  
 
ephedrine 
ephedrine 
dose(mg) 
atropine SPO2<95 
sensory 
blockade 
level 
N 0 N N T8 
Y 6 N N T8 
N 0 N N T8 
Y 6 N N T8 
N 0 N N T8 
N 0 N N T8 
Y 12 N N T6 
N 0 N N T8 
N 0 N N T10 
Y 12 N N T6 
N 0 N N T8 
N 0 N N T8 
Y 12 N N T6 
N 0 N N T8 
N 0 N N T8 
Y 18 N N T6 
N 0 N N T8 
N 0 N N T8 
Y 6 N N T8 
N 0 N N T8 
N 0 N N T8 
Y 6 N N T10 
N 0 N N T8 
N 0 N N T10 
Y 6 N N T8 
N 0 N N T8 
N 0 N N T10 
Y 6 N N T6 
N 0 N N T8 
N 0 N N T10 
 
  
 
 
 
name 
Age sex asa status ht wt Diag procedure preop sbp preop dbp 
preop 
map 
preop 
hr 
sbp1 dbp1 map1 hr1 
muthukumar 25 m ps1 170 68 RIH hernioplasty 132 83 118 88 132 71 92 92 
neelagandan 55 m ps2 165 50 RIH hernioplasty 119 80 93 68 109 63 78 72 
annamalai 57 m ps2 162 50 UH hernioplasty 138 76 98 79 130 85 96 88 
krishnakumar 51 m ps2 164 62 RIH hernioplasty 123 83 93 97 119 81 90 88 
Sundar 25 m ps1 170 65 RIH hernioplasty 124 83 97 85 120 83 95 73 
murugesan 65 m ps2 159 55 RIH hernioplasty 142 88 104 86 133 88 101 89 
ayyammal 48 f ps1 155 58 LIH hernioplasty 130 90 102 90 145 98 112 96 
perumal 43 m ps1 155 68 RIH hernioplasty 142 83 118 88 132 71 92 92 
gandhi 62 m ps2 158 50 RIH hernioplasty 109 80 93 68 109 63 78 72 
murugan 60 m ps2 170 50 UH hernioplasty 138 76 98 79 130 85 96 88 
kathiravan 64 m ps2 168 62 RIH hernioplasty 123 83 93 97 119 81 90 88 
manikandan 48 m ps1 165 65 RIH hernioplasty 124 83 97 85 120 83 95 73 
sivaraj 63 m ps2 162 55 RIH hernioplasty 132 88 104 86 133 88 101 89 
sirajul islam 25 m ps1 168 68 RIH hernioplasty 132 83 118 88 132 71 92 92 
pandurangan 64 m ps2 166 50 RIH hernioplasty 129 80 93 68 109 63 78 72 
paulraj 34 m ps2 158 50 UH hernioplasty 138 76 98 79 130 85 96 88 
dinavel 45 m ps2 165 62 RIH hernioplasty 134 84 95 92 123 83 93 97 
gopinath 40 m ps1 168 65 RIH hernioplasty 124 83 97 85 120 83 95 73 
moses 65 m ps2 159 55 RIH hernioplasty 132 88 104 86 133 88 101 89 
sudha 48 f ps1 155 58 LIH hernioplasty 130 90 102 90 145 98 112 96 
venkat sai 25 m ps1 170 68 RIH hernioplasty 132 83 118 88 132 71 92 92 
masilamani 55 m ps2 165 50 RIH hernioplasty 119 80 93 68 109 63 78 72 
chandra bose 57 m ps2 162 50 UH hernioplasty 138 76 98 79 130 85 96 88 
nagamani 51 m ps2 164 62 RIH hernioplasty 123 83 93 97 119 81 90 88 
rajasekar 25 m ps1 170 65 RIH hernioplasty 124 83 97 85 120 83 95 73 
ezhumalai 65 m ps2 159 55 RIH hernioplasty 142 88 104 86 133 88 101 89 
kanimozhi 48 f ps1 155 58 LIH hernioplasty 140 90 102 90 145 98 112 96 
santhosh 25 m ps1 170 68 RIH hernioplasty 132 83 118 88 132 71 92 92 
baskar 57 m ps2 162 50 UH hernioplasty 138 76 98 79 130 85 96 88 
latha 48 f ps1 155 58 LIH hernioplasty 140 90 102 90 145 98 112 96 
Master chart group C 
  
 
 
sbp2 dbp2 map2 hr2 sbp3 dbp3 map3 hr3 sbp4 dbp4 map4 hr4 sbp5 dbp5 map5 hr5 
137 64 89 91 137 64 95 89 133 59 94 91 132 55 86 83 
115 75 88 73 108 70 83 68 106 69 87 67 104 69 87 66 
129 70 88 99 152 85 100 103 146 78 99 106 142 72 98 92 
118 80 89 91 119 78 88 90 117 76 85 84 120 77 87 82 
122 84 97 81 122 85 97 77 123 82 96 67 124 82 96 68 
129 85 97 83 142 88 103 79 141 83 100 81 133 84 99 86 
152 92 110 81 148 92 110 79 148 90 109 82 143 89 105 82 
137 64 89 91 137 64 95 89 133 59 94 91 132 55 86 83 
115 75 88 73 108 70 83 68 106 69 87 67 104 69 87 66 
129 70 88 99 152 85 100 103 146 78 99 106 142 72 98 92 
118 80 89 91 119 78 88 90 117 76 85 84 120 77 87 82 
122 84 97 81 122 85 97 77 123 82 96 67 124 82 96 68 
129 85 97 83 142 88 103 79 141 83 100 81 133 84 99 86 
137 64 89 91 137 64 95 89 133 59 94 91 132 55 86 83 
115 75 88 73 108 70 83 68 106 69 87 67 104 69 87 66 
129 70 88 99 152 85 100 103 146 78 99 106 142 72 98 92 
119 81 90 88 118 80 89 91 119 78 88 90 117 76 85 84 
122 84 97 81 122 85 97 77 123 82 96 67 124 82 96 68 
129 85 97 83 142 88 103 79 141 83 100 81 133 84 99 86 
152 92 110 81 148 92 110 79 148 90 109 82 143 89 105 82 
137 64 89 91 137 64 95 89 133 59 94 91 132 55 86 83 
115 75 88 73 108 70 83 68 106 69 87 67 104 69 87 66 
129 70 88 99 152 85 100 103 146 78 99 106 142 72 98 92 
118 80 89 91 119 78 88 90 117 76 85 84 120 77 87 82 
122 84 97 81 122 85 97 77 123 82 96 67 124 82 96 68 
129 85 97 83 142 88 103 79 141 83 100 81 133 84 99 86 
152 92 110 81 148 92 110 79 148 90 109 82 143 89 105 82 
137 64 89 91 137 64 95 89 133 59 94 91 132 55 86 83 
129 70 88 99 152 85 100 103 146 78 99 106 142 72 98 92 
152 92 110 81 148 92 110 79 148 90 109 82 143 89 105 82 
 
 
  
 
sbp10 dbp10 map10 hr10 sbp15 dbp15 map15 hr15 sbp20 dbp20 map20 hr20 sbp25 dbp25 map25 hr25 
137 64 95 74 130 67 92 72 132 65 86 71 131 66 95 74 
104 67 79 63 103 67 79 66 107 65 77 60 100 65 77 60 
133 69 98 105 130 64 88 97 132 70 90 99 127 60 88 81 
111 66 79 83 109 67 78 81 111 73 82 70 112 72 81 81 
122 82 95 71 121 82 95 77 122 81 95 66 121 81 94 65 
131 86 99 78 128 81 94 75 127 81 93 69 142 84 102 67 
147 89 107 80 141 86 103 79 140 87 102 78 143 92 108 77 
137 64 95 74 130 67 92 72 132 65 86 71 131 66 95 74 
104 67 79 63 103 67 79 66 107 65 77 60 100 65 77 60 
133 69 98 105 130 64 88 97 132 70 90 99 127 60 88 81 
111 66 79 83 109 67 78 81 111 73 82 70 112 72 81 81 
122 82 95 71 121 82 95 77 122 81 95 66 121 81 94 65 
131 86 99 78 128 81 94 75 127 81 93 69 142 84 102 67 
137 64 95 74 130 67 92 72 132 65 86 71 131 66 95 74 
104 67 79 63 103 67 79 66 107 65 77 60 100 65 77 60 
133 69 98 105 130 64 88 97 132 70 90 99 127 60 88 81 
120 77 87 82 111 66 79 83 109 67 78 81 111 73 82 70 
122 82 95 71 121 82 95 77 122 81 95 66 121 81 94 65 
131 86 99 78 128 81 94 75 127 81 93 69 142 84 102 67 
147 89 107 80 141 86 103 79 140 87 102 78 143 92 108 77 
137 64 95 74 130 67 92 72 132 65 86 71 131 66 95 74 
104 67 79 63 103 67 79 66 107 65 77 60 100 65 77 60 
133 69 98 105 130 64 88 97 132 70 90 99 127 60 88 81 
111 66 79 83 109 67 78 81 111 73 82 70 112 72 81 81 
122 82 95 71 121 82 95 77 122 81 95 66 121 81 94 65 
131 86 99 78 128 81 94 75 127 81 93 69 142 84 102 67 
147 89 107 80 141 86 103 79 140 87 102 78 143 92 108 77 
137 64 95 74 130 67 92 72 132 65 86 71 131 66 95 74 
133 69 98 105 130 64 88 97 132 70 90 99 127 60 88 81 
147 89 107 80 141 86 103 79 140 87 102 78 143 92 108 77 
 
  
 
 
sbp30 dbp30 map30 hr30 sbp40 dbp40 map40 hr40 sbp50 dbp50 map50 hr50 sb60 dbp60 map60 hr60 u/o 60 
133 63 83 85 140 60 91 82 143 67 93 76 140 56 94 72 500 
100 65 77 57 100 66 77 59 102 67 77 65 105 68 80 69 1000 
111 56 82 79 122 56 82 79 125 59 88 76 130 75 100 88 500 
113 76 84 81 121 80 90 86 118 73 84 84 120 73 85 73 400 
120 81 94 67 123 79 94 74 123 77 92 60 119 77 91 62 800 
128 83 94 69 133 82 96 70 132 80 94 72 133 81 94 70 650 
145 87 104 78 131 86 99 76 141 85 102 76 141 85 100 76 1100 
133 63 83 85 140 60 91 82 143 67 93 76 140 56 94 72 500 
100 65 77 57 100 66 77 59 102 67 77 65 105 68 80 69 1000 
111 56 82 79 122 56 82 79 125 59 88 76 130 75 100 88 500 
113 76 84 81 121 80 90 86 118 73 84 84 120 73 85 73 400 
120 81 94 67 123 79 94 74 123 77 92 60 119 77 91 62 800 
128 83 94 69 133 82 96 70 132 80 94 72 133 81 94 70 900 
133 63 83 85 140 60 91 82 143 67 93 76 140 56 94 72 500 
100 65 77 57 100 66 77 59 102 67 77 65 105 68 80 69 1300 
111 56 82 79 122 56 82 79 125 59 88 76 130 75 100 88 500 
112 72 81 81 113 76 84 81 121 80 90 86 118 73 84 84 450 
120 81 94 67 123 79 94 74 123 77 92 60 119 77 91 62 750 
128 83 94 69 133 82 96 70 132 80 94 72 133 81 94 70 950 
145 87 104 78 131 86 99 76 141 85 102 76 141 85 100 76 1000 
133 63 83 85 140 60 91 82 143 67 93 76 140 56 94 72 550 
100 65 77 57 100 66 77 59 102 67 77 65 105 68 80 69 700 
111 56 82 79 122 56 82 79 125 59 88 76 130 75 100 88 550 
113 76 84 81 121 80 90 86 118 73 84 84 120 73 85 73 450 
120 81 94 67 123 79 94 74 123 77 92 60 119 77 91 62 850 
128 83 94 69 133 82 96 70 132 80 94 72 133 81 94 70 900 
145 87 104 78 131 86 99 76 141 85 102 76 141 85 100 76 1200 
133 63 83 85 140 60 91 82 143 67 93 76 140 56 94 72 600 
111 56 82 79 122 56 82 79 125 59 88 76 130 75 100 88 400 
145 87 104 78 131 86 99 76 141 85 102 76 141 85 100 76 1100 
  
 
 
sbp70 dbp70 map70 hr70 sbp80 dbp80 map80 hr80 sbp90 dbp90 map90 hr90 sbp100 dbp100 map100 hr100 
148 56 96 71 139 67 94 77 133 70 94 78     
108 70 80 70 112 78 88 78         
127 66 84 80 129 78 96 85 131 74 96 84 130 77 98 85 
111 73 82 75 112 75 83 79 119 76 89 75 122 81 91 77 
108 72 84 63 109 72 84 66 110 71 84 66 109 73 85 68 
128 81 92 74 121 78 89 72 121 83 109 76 127 84 108 74 
136 78 98 74 147 89 107 78 134 80 96 74     
148 56 96 71 139 67 94 77 133 70 94 78     
108 70 80 70 112 78 88 78         
127 66 84 80 129 78 96 85 131 74 96 84 130 77 98 85 
111 73 82 75 112 75 83 79 119 76 89 75 122 81 91 77 
108 72 84 63 109 72 84 66 110 71 84 66 109 73 85 68 
128 81 92 74 121 78 89 72 121 83 109 76 127 84 108 74 
148 56 96 71 139 67 94 77 133 70 94 78     
108 70 80 70 112 78 88 78         
127 66 84 80 129 78 96 85 131 74 96 84 130 77 98 85 
120 73 85 73 111 73 82 75 112 75 83 79 119 76 89 75 
108 72 84 63 109 72 84 66 110 71 84 66 109 73 85 68 
128 81 92 74 121 78 89 72 121 83 109 76 127 84 108 74 
136 78 98 74 147 89 107 78 134 80 96 74     
148 56 96 71 139 67 94 77 133 70 94 78     
108 70 80 70 112 78 88 78         
127 66 84 80 129 78 96 85 131 74 96 84 130 77 98 85 
111 73 82 75 112 75 83 79 119 76 89 75 122 81 91 77 
108 72 84 63 109 72 84 66 110 71 84 66 109 73 85 68 
128 81 92 74 121 78 89 72 121 83 109 76 127 84 108 74 
136 78 98 74 147 89 107 78 134 80 96 74     
148 56 96 71 139 67 94 77 133 70 94 78     
127 66 84 80 129 78 96 85 131 74 96 84 130 77 98 85 
136 78 98 74 147 89 107 78 134 80 96 74     
 
  
 
sbp70 dbp70 map70 hr70 sbp80 dbp80 map80 hr80 sbp90 dbp90 map90 hr90 sbp100 dbp100 map100 hr100 
148 56 96 71 139 67 94 77 133 70 94 78     
108 70 80 70 112 78 88 78         
127 66 84 80 129 78 96 85 131 74 96 84 130 77 98 85 
111 73 82 75 112 75 83 79 119 76 89 75 122 81 91 77 
108 72 84 63 109 72 84 66 110 71 84 66 109 73 85 68 
128 81 92 74 121 78 89 72 121 83 109 76 127 84 108 74 
136 78 98 74 147 89 107 78 134 80 96 74     
148 56 96 71 139 67 94 77 133 70 94 78     
108 70 80 70 112 78 88 78         
127 66 84 80 129 78 96 85 131 74 96 84 130 77 98 85 
111 73 82 75 112 75 83 79 119 76 89 75 122 81 91 77 
108 72 84 63 109 72 84 66 110 71 84 66 109 73 85 68 
128 81 92 74 121 78 89 72 121 83 109 76 127 84 108 74 
148 56 96 71 139 67 94 77 133 70 94 78     
108 70 80 70 112 78 88 78         
127 66 84 80 129 78 96 85 131 74 96 84 130 77 98 85 
120 73 85 73 111 73 82 75 112 75 83 79 119 76 89 75 
108 72 84 63 109 72 84 66 110 71 84 66 109 73 85 68 
128 81 92 74 121 78 89 72 121 83 109 76 127 84 108 74 
136 78 98 74 147 89 107 78 134 80 96 74     
148 56 96 71 139 67 94 77 133 70 94 78     
108 70 80 70 112 78 88 78         
127 66 84 80 129 78 96 85 131 74 96 84 130 77 98 85 
111 73 82 75 112 75 83 79 119 76 89 75 122 81 91 77 
108 72 84 63 109 72 84 66 110 71 84 66 109 73 85 68 
128 81 92 74 121 78 89 72 121 83 109 76 127 84 108 74 
136 78 98 74 147 89 107 78 134 80 96 74     
148 56 96 71 139 67 94 77 133 70 94 78     
127 66 84 80 129 78 96 85 131 74 96 84 130 77 98 85 
136 78 98 74 147 89 107 78 134 80 96 74     
 
 
  
 
ephedrine ephedrine dose(mg) atropine SPO2<95 sensory blockade level 
N 0 N N T8 
N 0 N N T8 
N 0 N N T10 
N 0 N N T8 
N 0 N N T8 
N 0 N N T6 
N 0 N N T8 
N 0 N N T10 
N 0 N N T8 
N 0 N N T6 
N 0 N N T6 
N 0 N N T8 
N 0 N N T6 
N 0 N N T6 
N 0 N N T8 
N 0 N N T10 
N 0 N N T6 
N 0 N N T8 
N 0 N N T8 
N 0 N N T6 
N 0 N N T10 
Y 6 N N T8 
N 0 N N T8 
N 0 N N T8 
N 0 N N T8 
N 0 N N T8 
N 0 N N T6 
N 0 N N T6 
N 0 N N T8 
N 0 N N T8 
 
 
  
 
name age sex asa status height weight diagnosis procedure preop sbp preop dbp preop 
map 
preop hr sbp1 dbp1 map1 hr1 
muthukumar 25 m ps1 170 68 RIH hernioplas
ty 
142 83 118 88 132 71 92 92 
neelagandan 55 m ps2 165 50 rt inguinal 
hernia 
hernioplas
ty 
119 80 93 68 109 63 78 72 
annamalai 57 m ps2 162 50 umblical 
hernia 
hernioplas
ty 
148 76 98 79 130 85 96 88 
krishnakumar 51 m ps2 164 62 rt inguinal 
hernia 
hernioplas
ty 
123 83 93 97 119 81 90 88 
Sundar 25 m ps1 170 65 rt inguinal 
hernia 
hernioplas
ty 
124 83 97 85 120 83 95 73 
murugesan 65 m ps2 159 55 rt inguinal 
hernia 
hernioplas
ty 
142 88 104 86 133 88 101 89 
ayyammal 48 f ps1 155 58 lt inguinal 
hernia 
hernioplas
ty 
140 90 102 90 145 98 112 96 
perumal 43 m ps1 155 68 rt inguinal 
hernia 
hernioplas
ty 
142 83 118 88 132 71 92 92 
gandhi 62 m ps2 158 50 rt inguinal 
hernia 
hernioplas
ty 
109 80 93 68 109 63 78 72 
murugan 60 m ps2 170 50 umblical 
hernia 
hernioplas
ty 
148 76 98 79 130 85 96 88 
kathiravan 64 m ps2 168 62 rt inguinal 
hernia 
hernioplas
ty 
123 83 93 97 119 81 90 88 
manikandan 48 m ps1 165 65 rt inguinal 
hernia 
hernioplas
ty 
124 83 97 85 120 83 95 73 
sivaraj 63 m ps2 162 55 rt inguinal 
hernia 
hernioplas
ty 
142 88 104 86 133 88 101 89 
sirajul islam 25 m ps1 168 68 rt inguinal 
hernia 
hernioplas
ty 
142 83 118 88 132 71 92 92 
pandurangan 64 m ps2 166 50 rt inguinal 
hernia 
hernioplas
ty 
129 80 93 68 109 63 78 72 
paulraj 34 m ps2 158 50 umblical 
hernia 
hernioplas
ty 
148 76 98 79 130 85 96 88 
dinavel 45 m ps2 165 62 rt inguinal 
hernia 
hernioplas
ty 
134 84 95 92 123 83 93 97 
gopinath 40 m ps1 168 65 rt inguinal 
hernia 
hernioplas
ty 
124 83 97 85 120 83 95 73 
moses 65 m ps2 159 55 rt inguinal 
hernia 
hernioplas
ty 
142 88 104 86 133 88 101 89 
sudha 48 f ps1 155 58 lt inguinal 
hernia 
hernioplas
ty 
140 90 102 90 145 98 112 96 
venkat sai 25 m ps1 170 68 rt inguinal 
hernia 
hernioplas
ty 
142 83 118 88 132 71 92 92 
masilamani 55 m ps2 165 50 rt inguinal 
hernia 
hernioplas
ty 
119 80 93 68 109 63 78 72 
chandra bose 57 m ps2 162 50 umblical 
hernia 
hernioplas
ty 
148 76 98 79 130 85 96 88 
nagamani 51 m ps2 164 62 rt inguinal 
hernia 
hernioplas
ty 
123 83 93 97 119 81 90 88 
rajasekar 25 m ps1 170 65 rt inguinal 
hernia 
hernioplas
ty 
124 83 97 85 120 83 95 73 
ezhumalai 65 m ps2 159 55 rt inguinal 
hernia 
hernioplas
ty 
142 88 104 86 133 88 101 89 
kanimozhi 48 f ps1 155 58 lt inguinal 
hernia 
inguinal 
hernia 
140 90 102 90 145 98 112 96 
santhosh 25 m ps1 170 68 rt inguinal 
hernia 
hernioplas
ty 
142 83 118 88 132 71 92 92 
baskar 57 m ps2 162 50 umblical 
hernia 
hernioplas
ty 
148 76 98 79 130 85 96 88 
latha 48 f ps1 155 58 lt inguinal 
hernia 
hernioplas
ty 
140 90 102 90 145 98 112 96 
 
Master chart group D 
  
 
sbp2 dbp2 map2 hr2 sbp3 dbp3 map3 hr3 sbp4 dbp4 map4 hr4 sbp5 dbp5 map5 hr5 
106 74 98 80 120 79 89 75 112 77 84 73 111 72 81 73 
96 46 64 78 95 53 68 74 94 54 67 86 98 48 63 84 
115 76 90 58 121 78 100 62 134 81 98 60 130 68 88 60 
142 91 105 74 149 93 111 86 150 94 111 82 159 93 115 74 
111 85 90 80 106 74 98 80 120 79 89 75 112 77 84 73 
96 46 64 78 95 53 68 74 94 54 67 86 98 48 63 84 
142 91 105 74 149 93 111 86 150 94 111 82 159 93 115 74 
115 76 90 58 121 78 100 62 134 81 98 60 130 68 88 60 
106 74 98 80 120 79 89 75 112 77 84 73 111 72 81 73 
96 46 64 78 95 53 68 74 94 54 67 86 98 48 63 84 
142 91 105 74 149 93 111 86 150 94 111 82 159 93 115 74 
96 46 64 78 95 53 68 74 94 54 67 86 98 48 63 84 
106 74 98 80 120 79 89 75 112 77 84 73 111 72 81 73 
115 76 90 58 121 78 100 62 134 81 98 60 130 68 88 60 
142 91 105 74 149 93 111 86 150 94 111 82 159 93 115 74 
96 46 64 78 95 53 68 74 94 54 67 86 98 48 63 84 
106 74 98 80 120 79 89 75 112 77 84 73 111 72 81 73 
115 76 90 58 121 78 100 62 134 81 98 60 130 68 88 60 
142 91 105 74 149 93 111 86 150 94 111 82 159 93 115 74 
96 46 64 78 95 53 68 74 94 54 67 86 98 48 63 84 
106 74 98 80 120 79 89 75 112 77 84 73 111 72 81 73 
115 76 90 58 121 78 100 62 134 81 98 60 130 68 88 60 
142 91 105 74 149 93 111 86 150 94 111 82 159 93 115 74 
96 46 64 78 95 53 68 74 94 54 67 86 98 48 63 84 
106 74 98 80 120 79 89 75 112 77 84 73 111 72 81 73 
115 76 90 58 121 78 100 62 134 81 98 60 130 68 88 60 
142 91 105 74 149 93 111 86 150 94 111 82 159 93 115 74 
115 76 90 58 121 78 100 62 134 81 98 60 130 68 88 60 
96 46 64 78 95 53 68 74 94 54 67 86 98 48 63 84 
106 74 98 80 120 79 89 75 112 77 84 73 111 72 81 73 
 
  
 
sbp10 dbp10 map10 hr10 sbp15 dbp15 map15 hr15 sbp20 dbp20 map20 hr20 sbp25 dbp25 map25 hr25 
110 71 81 70 105 68 78 66 108 67 78 72 118 65 80 77 
104 50 68 88 107 50 69 88 105 52 68 85 109 56 75 80 
134 78 99 61 146 84 111 58 155 88 122 60 166 89 119 60 
156 89 109 68 145 87 105 67 145 84 102 65 161 87 110 62 
111 72 81 73 110 71 81 70 105 68 78 66 108 67 78 72 
104 50 68 88 107 50 69 88 105 52 68 85 109 56 75 80 
156 89 109 68 145 87 105 67 145 84 102 65 161 87 110 62 
134 78 99 61 146 84 111 58 155 88 122 60 166 89 119 60 
110 71 81 70 105 68 78 66 108 67 78 72 118 65 80 77 
104 50 68 88 107 50 69 88 105 52 68 85 109 56 75 80 
156 89 109 68 145 87 105 67 145 84 102 65 161 87 110 62 
104 50 68 88 107 50 69 88 105 52 68 85 109 56 75 80 
110 71 81 70 105 68 78 66 108 67 78 72 118 65 80 77 
134 78 99 61 146 84 111 58 155 88 122 60 166 89 119 60 
156 89 109 68 145 87 105 67 145 84 102 65 161 87 110 62 
104 50 68 88 107 50 69 88 105 52 68 85 109 56 75 80 
110 71 81 70 105 68 78 66 108 67 78 72 118 65 80 77 
134 78 99 61 146 84 111 58 155 88 122 60 166 89 119 60 
156 89 109 68 145 87 105 67 145 84 102 65 161 87 110 62 
104 50 68 88 107 50 69 88 105 52 68 85 109 56 75 80 
110 71 81 70 105 68 78 66 108 67 78 72 118 65 80 77 
134 78 99 61 146 84 111 58 155 88 122 60 166 89 119 60 
156 89 109 68 145 87 105 67 145 84 102 65 161 87 110 62 
104 50 68 88 107 50 69 88 105 52 68 85 109 56 75 80 
110 71 81 70 105 68 78 66 108 67 78 72 118 65 80 77 
134 78 99 61 146 84 111 58 155 88 122 60 166 89 119 60 
156 89 109 68 145 87 105 67 145 84 102 65 161 87 110 62 
134 78 99 61 146 84 111 58 155 88 122 60 166 89 119 60 
104 50 68 88 107 50 69 88 105 52 68 85 109 56 75 80 
110 71 81 70 105 68 78 66 108 67 78 72 118 65 80 77 
 
  
 
sbp30 dbp30 map30 hr30 sbp40 dbp40 map40 hr40 sbp50 dbp50 map50 hr50 sb60 dbp60 map60 hr60 u/o 60 
114 75 83 76 115 75 83 76 118 74 85 67 121 72 84 78 1200 
113 52 76 84 114 55 68 80 114 53 70 86 119 59 77 85 450 
159 89 120 61 144 76 103 59 136 72 98 60 134 86 99 61 850 
152 83 105 70 144 79 97 65 147 84 104 67 131 82 95 74 550 
118 65 80 77 114 75 83 76 115 75 83 76 118 74 85 67 1000 
113 52 76 84 114 55 68 80 114 53 70 86 119 59 77 85 400 
152 83 105 70 144 79 97 65 147 84 104 67 131 82 95 74 500 
159 89 120 61 144 76 103 59 136 72 98 60 134 86 99 61 800 
114 75 83 76 115 75 83 76 118 74 85 67 121 72 84 78 1050 
113 52 76 84 114 55 68 80 114 53 70 86 119 59 77 85 450 
152 83 105 70 144 79 97 65 147 84 104 67 131 82 95 74 550 
113 52 76 84 114 55 68 80 114 53 70 86 119 59 77 85 450 
114 75 83 76 115 75 83 76 118 74 85 67 121 72 84 78 1300 
159 89 120 61 144 76 103 59 136 72 98 60 134 86 99 61 850 
152 83 105 70 144 79 97 65 147 84 104 67 131 82 95 74 550 
113 52 76 84 114 55 68 80 114 53 70 86 119 59 77 85 450 
114 75 83 76 115 75 83 76 118 74 85 67 121 72 84 78 650 
159 89 120 61 144 76 103 59 136 72 98 60 134 86 99 61 850 
152 83 105 70 144 79 97 65 147 84 104 67 131 82 95 74 550 
113 52 76 84 114 55 68 80 114 53 70 86 119 59 77 85 450 
114 75 83 76 115 75 83 76 118 74 85 67 121 72 84 78 900 
159 89 120 61 144 76 103 59 136 72 98 60 134 86 99 61 850 
152 83 105 70 144 79 97 65 147 84 104 67 131 82 95 74 450 
113 52 76 84 114 55 68 80 114 53 70 86 119 59 77 85 350 
114 75 83 76 115 75 83 76 118 74 85 67 121 72 84 78 1000 
159 89 120 61 144 76 103 59 136 72 98 60 134 86 99 61 850 
152 83 105 70 144 79 97 65 147 84 104 67 131 82 95 74 650 
159 89 120 61 144 76 103 59 136 72 98 60 134 86 99 61 950 
113 52 76 84 114 55 68 80 114 53 70 86 119 59 77 85 550 
114 75 83 76 115 75 83 76 118 74 85 67 121 72 84 78 1100 
 
  
 
sbp70 dbp70 map70 hr70 sbp80 dbp80 map80 hr80 sbp90 dbp90 map90 hr90 sbp100 dbp100 map100 hr100 
122 72 85 73 121 79 89 69 117 75 85 69 114 81 88 72 
113 59 77 87 120 61 80 90 123 60 84 75 126 70 87 94 
121 78 93 60 123 76 94 58 120 74 84 76 116 69 85 74 
127 77 87 69 129 81 93 73 120 75 87 71 122 74 86 76 
121 72 84 78 122 72 85 73 121 79 89 69 117 75 85 69 
113 59 77 87 120 61 80 90 123 60 84 75 126 70 87 94 
127 77 87 69 129 81 93 73 120 75 87 71 122 74 86 76 
121 78 93 60 123 76 94 58 120 74 84 76 116 69 85 74 
122 72 85 73 121 79 89 69 117 75 85 69 114 81 88 72 
113 59 77 87 120 61 80 90 123 60 84 75 126 70 87 94 
127 77 87 69 129 81 93 73 120 75 87 71 122 74 86 76 
113 59 77 87 120 61 80 90 123 60 84 75 126 70 87 94 
122 72 85 73 121 79 89 69 117 75 85 69 114 81 88 72 
121 78 93 60 123 76 94 58 120 74 84 76 116 69 85 74 
127 77 87 69 129 81 93 73 120 75 87 71 122 74 86 76 
113 59 77 87 120 61 80 90 123 60 84 75 126 70 87 94 
122 72 85 73 121 79 89 69 117 75 85 69 114 81 88 72 
121 78 93 60 123 76 94 58 120 74 84 76 116 69 85 74 
127 77 87 69 129 81 93 73 120 75 87 71 122 74 86 76 
113 59 77 87 120 61 80 90 123 60 84 75 126 70 87 94 
122 72 85 73 121 79 89 69 117 75 85 69 114 81 88 72 
121 78 93 60 123 76 94 58 120 74 84 76 116 69 85 74 
127 77 87 69 129 81 93 73 120 75 87 71 122 74 86 76 
113 59 77 87 120 61 80 90 123 60 84 75 126 70 87 94 
122 72 85 73 121 79 89 69 117 75 85 69 114 81 88 72 
121 78 93 60 123 76 94 58 120 74 84 76 116 69 85 74 
127 77 87 69 129 81 93 73 120 75 87 71 122 74 86 76 
121 78 93 60 123 76 94 58 120 74 84 76 116 69 85 74 
113 59 77 87 120 61 80 90 123 60 84 75 126 70 87 94 
122 72 85 73 121 79 89 69 117 75 85 69 114 81 88 72 
 
  
 
ephedrine ephedrine atropine SPO2<95 sensory step downto 5 mcg/kg/mt time of stepdown(mt) 
N 0 N N T6 N  
N 0 N N T8 N  
N 0 N N T10 Y 25 
N 0 N N T8 Y 25 
N 0 N N T8 N  
N 0 N N T6 N  
N 0 N N T8 Y 20 
N 0 N N T8 Y 25 
N 0 N N T8 N  
N 0 N N T6 N  
N 0 N N T8 Y 30 
N 0 N N T8 N  
N 0 N N T8 N  
N 0 N N T10 Y 25 
N 0 N N T8 Y 20 
N 0 N N T6 N  
N 0 N N T6 N  
N 0 N N T10 Y 25 
N 0 N N T8 Y 30 
N 0 N N T6 N  
N 0 N N T6 N  
N 0 N N T8 Y 25 
N 0 N N T8 Y 25 
N 0 N N T8 N  
N 0 N N T8 N  
N 0 N N T10 Y 20 
N 0 N N T8 Y 20 
N 0 N N T10 Y 25 
N 0 N N T6 N  
N 0 N N T8 N  
 
